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The  recent  epidemics  of metabolic  diseases,  obesity,  type  2  diabetes(T2D),  liver lipid  disorders  and
metabolic  syndrome  have  largely  been  attributed  to genetic  background  and  changes  in diet,  exercise
and  aging.  However,  there  is now  considerable  evidence  that  other  environmental  factors  may  contribute
to  the  rapid  increase  in  the  incidence  of  these  metabolic  diseases.  This  review  will  examine  changes  to
the  incidence  of  obesity,  T2D  and  non-alcoholic  fatty  liver  disease  (NAFLD),  the contribution  of  genetics
to  these  disorders  and  describe  the  role  of  the endocrine  system  in  these  metabolic  disorders.  It  will  then
speciﬁcally  focus  on  the role  of  endocrine  disrupting  chemicals  (EDCs)  in  the  etiology  of  obesity,  T2Dbesogens
etabolism disruptors
evelopmental origins of health and
isease
besity
iabetes
and  NAFLD  while  ﬁnally  integrating  the  information  on  EDCs  on  multiple  metabolic  disorders  that  could
lead  to  metabolic  syndrome.  We  will speciﬁcally  examine  evidence  linking  EDC  exposures  during  critical
periods  of development  with  metabolic  diseases  that manifest  later  in  life  and across  generations.
Published  by  Elsevier  Inc.  This  is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://
creativecommons.org/licenses/by-nc-nd/4.0/).ipid disorders
. Introduction
Metabolic syndrome (MetS) is a complex condition charac-
erized by insulin resistance, abdominal obesity, dyslipidemia,
ypertension, and hyperglycemia; it is a risk factor for cardiovas-
ular disease, T2D, stroke, chronic kidney disease and cancers [1,2].
ts prevalence is increasing along with the increase in obesity, andPlease cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
t is reaching epidemic proportions affecting between 24% and 34%
f the adult US population [3].
∗ Corresponding author at: Division of Extramural Research and Training, National
nstitute of Environmental Health Sciences, 12233 TW Alexander Drive, RTP, NC
7709, USA.
E-mail address: heindelj@niehs.nih.gov (J.J. Heindel).
ttp://dx.doi.org/10.1016/j.reprotox.2016.10.001
890-6238/Published by Elsevier Inc. This is an open access article under the CC BY-NC-NIn the medical community, epidemics of metabolic diseases
have largely been attributed to genetic background and changes in
diet, exercise and aging. However, there is now considerable evi-
dence that other environmental factors may contribute to the rapid
increase in the incidence of obesity, T2D and other aspects of MetS
observed over the past three decades [4]. One environmental fac-
tor that has begun to receive attention is a class of chemicals that
can interfere with the action of hormones including metabolic hor-
mones. These compounds, termed EDCs, are found in a wide variety
of consumer products, and exposures are often widespread [5] Of
particular concern is evidence that exposure to EDCs during critical
periods when adipocytes are differentiating and the pancreas, liver,pting chemicals and metabolic disorders, Reprod Toxicol (2016),
brain, etc. are developing can induce effects that manifest later in
life, often as overt disease.
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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This review will examine changes to the incidence of obesity,
2D and NAFLD and its associated hyperlipidemia, the contribu-
ion of genetics and describe the role of the endocrine system in
hese metabolic disorders. It will then speciﬁcally focus on the role
f EDCs in metabolic diseases, focusing on their role in the etiology
f obesity, T2D and NAFLD while ﬁnally integrating the information
n EDCs on multiple metabolic disorders that could lead to MetS.
e will speciﬁcally examine evidence linking EDC exposures dur-
ng critical periods of development with metabolic diseases that
anifest later in life and across generations.
. Metabolic diseases
.1. Obesity
Obesity is a global epidemic that affects infants, children and
dults [6]. The global prevalence of obesity has nearly doubled over
he past three decades and in the US it is the highest recorded
n human history [7]. For the ﬁrst time worldwide, the number
f obese and overweight people is greater than the number of
hose who are underweight [8]. This dramatic increase in the rate
f abdominal obesity has been observed in both developed and
eveloping countries [9,10].
Obesity among children and adolescents has similarly increased
6]. Approximately one third of US children are overweight or
bese, and over 60% of obese children will become obese adults
11]. There is also an obesity epidemic among infants six months
f age and younger; an age group where food choices and limited
hysical activity cannot explain this outcome [12].
The obesity epidemic is not limited to humans but has also been
bserved as upward trends in body weight among primates and
odents living in research colonies, as well as among feral rodents,
orses and domestic dogs and cats [13].
Staggering health care costs are associated with treating the
o-morbidities that typically accompany obesity [14] including
ardiovascular disease, hypertension, dyslipidemia, liver and gall-
ladder disease, insulin resistance, hyperglycemia and T2D [9].
besity is also associated with neurodegenerative diseases, can-
ers and obstructive sleep apnea. Thus, determining the factors that
ontribute to obesity has become a major public health issue.
.2. Type 2 diabetes
The American Diabetes Association (ADA) deﬁnes Diabetes Mel-
itus (DM) as: “a group of metabolic diseases characterized by
yperglycemia resulting from defects in insulin secretion, insulin
ction, or both” [15]. DM can result from a deterioration in function
nd/or a loss of mass of pancreatic tissue [16]. T2D (formerly known
s adult-onset or non-insulin-dependent diabetes or DM)  accounts
or 90–95% of diabetes cases and is characterized by increased
nsulin resistance and pancreatic beta cell dysfunction. More than
1% of individuals in the US older than 20 have diagnosed or undi-
gnosed T2D [7] and another 35% are estimated to be pre-diabetic.
he World Health Organization (WHO) estimates that 347 million
eople globally suffer from diabetes (90% of which is T2D) [17]. Ado-
escents and even children have experienced signiﬁcant increases
n the prevalence of this disease over short periods [14,18].
Obesity is the main environmental factor driving the increased
ncidence of T2D; 70% of the risk associated with T2D is related
o weight gain. Obesity is associated with insulin resistance that
romotes beta cell proliferation, leading to hyperinsulinemia typ-Please cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
cal of early stages of T2D and MetS. However, obesity is neither
ecessary nor sufﬁcient to cause T2D; these conditions can occur
ndependently. Indeed, 20% of adults with T2D were not overweight
nd 57% of obese individuals do not have T2D [19]. PRESS
icology xxx (2016) xxx–xxx
2.3. Nonalcoholic fatty liver disease and hyperlipidemia
Liver is the central organ for lipid metabolism. Nonalcoholic
fatty liver disease (NAFLD), characterized by excess triglyceride
accumulation within hepatocytes, or steatosis, is considered by
some to be the hepatic manifestation of obesity and MetS. NAFLD
is the most common liver disease, and it affects 25% of the global
population [20] and almost 8% of children [21]. NAFLD and its more
severe form, nonalcoholic steatohepatitis (NASH), are associated
with increased liver-related and overall mortality [20], and NAFLD
is a risk factor for cardiovascular disease [22]. The metabolic con-
dition most commonly associated with NAFLD is hyperlipidemia
(69%), although NAFLD is also associated with obesity (51%), MetS
(43%) and T2D (23%) [20]. NAFLD was initially thought to occur pre-
dominantly in women  [23] but increasing evidence indicates that
males and perhaps post-menopausal females are more susceptible
to NAFLD [21,24].
Hyperlipidemia is an elevation in blood triglycerides (hyper-
triglyceridemia), cholesterol (hypercholesterolemia), phospho-
lipids, or a combination thereof. While there is an association
between NAFLD and hyperlipidemia, not all patients with one
disorder are affected by the other. The prevalence of hypertriglyc-
eridemia in US adults is 25%, although it declined from 33% in
2001–2004 [25]. Total and LDL cholesterol have also been declining,
and these favorable changes may  be attributed to increased aware-
ness and utilization of lipid lowering medications [26]. Among
adolescents and US children, the prevalence of hyperlipidemia was
20% (1999–2012) [27].
2.4. Metabolic syndrome
The International Diabetes Federation estimates that 20–25%
of the world’s adult population have MetS, which it deﬁnes as:
“a cluster of the most dangerous heart attack risk factors: dia-
betes and prediabetes, abdominal obesity, high cholesterol and
high blood pressure” (https://www.idf.org/metabolic-syndrome).
The etiology of MetS is still a matter of research but insulin resis-
tance and central obesity are signiﬁcant contributors. Although
there is still substantial debate, it is likely that components of MetS
arise from insulin resistance. When insulin resistance occurs, there
is an increase of fasting glucose and impaired glucose tolerance,
often due to the abnormal expression of gluconeogenic enzymes.
This metabolic state induces further insulin release, ultimately
resulting in hyperinsulinemia. Hyperinsulinemia then simulates
transcription factors such as Srebp-1c in the liver, which drive
hypertriglyceridemia and hepatic steatosis [28]. In addition, the
overproduction and secretion of insulin by pancreatic -cells can
result in their exhaustion and death, initiating the onset of T2D.
The most prevalent form of insulin resistance is associated with
abdominal obesity and dysfunction of adipose tissue, indicating an
important central role for obesity in MetS.
2.5. Genetic contributions to metabolic diseases
2.5.1. Genetic factors in obesity
While the hereditary origins of obesity have long been assumed,
a genetic contribution to obesity became evident only in the last
two decades [29]. Evidence from twins and animal studies indi-
cates that genetic factors account for 40–70% of the variation in
BMI  [30–33]. Although several single genes are linked to obe-
sity, studies have conﬁrmed that the genetic basis of high BMI  is
mainly polygenic (i.e., resulting from polymorphisms in severalpting chemicals and metabolic disorders, Reprod Toxicol (2016),
genes that are associated with appetite and metabolism) or results
from single nucleotide polymorphisms [SNPs] rather than a single
gene mutation [34]. Three SNPs are signiﬁcantly related to obesity:
one in FTO (fat mass and the obesity-associated gene), one near
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MEM18 (transmembrane protein 18) and one near MC4R (mela-
ocortin 4 receptor) [29,34–36]. Only rare forms of obesity, usually
arts of genetic syndromes, result from a single gene mutation or
hromosomal abnormalities such as Prader- Willi and Bardet-Biedl
yndromes [37]. Because many people who carry genetic variants
inked to increased BMI  are not obese, it is anticipated that other
nvironmental factors can inﬂuence these genetic predispositions.
.5.2. Genetic factors in diabetes
Genetic factors are involved in the development of both type 1
nd T2D. The most prominent genetic factor known to be associated
ith type 1 diabetes is located in the region of chromosome 6 that
ontains the highly polymorphic HLA class II genes and controls
mmune responsiveness [38]. Recently, whole-genome investiga-
ions have detected more than 20 other genetic variants associated
ith type 1 diabetes [39].
Twin and family studies have provided strong evidence that T2D
lso has a solid genetic predisposition [40–42]. Genome wide asso-
iation studies (GWAS) identiﬁed genetic variants associated with
2D; most of the loci identiﬁed are related to lipid metabolism,
besity and -cell pathways [43,44]. TCF7L2 demonstrated the
trongest effect of >70 loci associated with the disease [43]. Similar
o the genetic basis for obesity, it is assumed that predisposition to
2D involves multiple genes and SNPs.
.5.3. Genetic factors in lipid disorder metabolism
Genetic predisposition to several lipid metabolism disorders
as demonstrated based on twin and family studies with estimates
hat 40% to 80% of the variance in blood lipid levels results from
enetic polymorphisms [45–47]. Familial hypercholesterolemia is
n autosomal dominant disease characterized by elevated blood
ow-density lipoprotein levels (LDL). More than 150 mutations
n the LDL receptor gene and in genes encoding the proteins
polipoprotein B (APOB), proprotein convertase subtilisin/kexin
ype 9 (PCSK9) and low density lipoprotein receptor adaptor pro-
ein 1 (LDLRAP1) that interact with the LDL receptor, are associated
ith the disease [48,49].
High levels of very low-density lipoprotein (VLDL) and triglyc-
rides characterize hypertriglyceridemia. The hereditary form of
his disease can result from mutations in genes that regulate the
etabolism of triglyceride rich lipoproteins such as apolipopro-
ein A5 (APOA5) LPL, apolipoprotein C2 (APOC2), lipase maturation
actor-1 (LMF1) and glycosylphosphatidylinositol anchored high
ensity lipoprotein binding protein 1 (GPIHBP1). Hypobetalipopro-
einemia is an autosomal dominant disease associated with low
evels of LDL cholesterol and APOB-containing lipoproteins. Muta-
ions in APOB and PCSK9 genes are common among patients [50].
.5.4. Genetic factors in NAFLD
Genetics have also been shown to contribute to variability in
he occurrence of NAFLD [51]. In recent years, GWAS have identi-
ed two major genetic determinants associated with NAFLD. The
ost signiﬁcant genetic linkage identiﬁed to date is a SNP in the
ene patatin-like phospholipase domain-containing 3 (PNPLA3), a
ene involved in the remodeling of hepatocellular lipid droplets
52]. This variant alters the mobilization of fatty acid, inhibits the
ctivity of lipases and can cause hepatocellular accumulation of
riglycerides [53]. Carriers of this genetic variant have increased
usceptibility to liver damage when exposed to environmentalPlease cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
tressors [53]. Another SNP in transmembrane six superfamily
ember 2 (TM6SF2) has been linked with NAFLD. This gene variant
s located on chromosome 19 and associated with increased hepatic
riglyceride content and lower serum lipoproteins [54,55]. PRESS
icology xxx (2016) xxx–xxx 3
3. Overview of tissues and hormones controlling
metabolism
The endocrine system controls the tissues and organs that
regulate weight and metabolism. Hormones and growth factors
including estrogens, androgens, glucocorticoids, insulin and thy-
roid hormones (among others) regulate the pathways that control
the number and content of adipocytes as well as appetite, satiety
and energy balance [56–59]. Other hormones affect metabolism
via actions in the gastrointestinal tract [ghrelin, cholecystokinin
(CCK), glucagon like peptide (GLP-1)], the pancreas (insulin,
glucagon), muscle (insulin), liver (glucagon, insulin, FGF21), adi-
pose tissue (leptin, adiponection, and a variety of other factors),
immune system, and brain [Neuropeptide Y (NPY), agouti related
protein (AgRP), pro-opiomelanocortin (POMC), alpha melanocyte-
stimulating hormone (alpha MSH)] [56–60]. These and other
hormones, growth factors and neurotransmitters control the hedo-
nic pathways in the brain that regulate food reward mechanisms,
food cravings and addiction [61–63]. They also control glucose and
lipid levels via pancreatic, muscle and liver responses. The pan-
creas responds to rising blood glucose levels by releasing insulin,
which then promotes glucose uptake into tissues. It also responds
to falling glucose levels in the blood by releasing glucagon, which
acts on the liver to stimulate glycogenolysis and gluconeogene-
sis to raise blood sugar. The liver also regulates glucose and lipid
metabolism via a number of nuclear hormone receptors including
aryl hydrocarbon receptor − AhR, pregnane x receptor − PXR, and
the constitutive androstane receptor − CAR.
Below we  focus on the endocrine control of adipogenesis, glu-
cose homeostasis and liver lipids.
3.1. Neuroendocrine control
The neuroendocrine hypothalamus, together with some struc-
tures in the brainstem, plays a key role in the regulation of energy
balance through the integration of peripheral signals and onward
signal transmission (Fig. 1). Peripheral signals conveying informa-
tion about meal processing, gastrointestinal activity, and changes
in energy stores access the brain via a number of routes, crossing or
by-passing the blood-brain barrier from the systemic circulation, or
changing the ﬁring rate of vagal or other sensory nerve ﬁbers. In the
medulla, the nucleus of the solitary tract and the area postrema are
key sites for the integration of these peripheral signals and for send-
ing them to other integration sites located in the hypothalamus (for
reviews see [64,65]).
The hypothalamus participates in the regulation of food intake
and body weight with two neuroendocrine components: the affer-
ent peripheral system (stimulated in response to a meal) and
the efferent system (regulating the feeding behavior and energy
metabolism) [66,67]. The peripheral signals are the hormones
insulin (secreted by the endocrine pancreas in response to changes
in blood sugar), leptin (secreted by adipocytes in proportion to
fat mass), ghrelin and orexin-A (secreted by the stomach and the
gut) [68]. These hormones link the control of peripheral energy
metabolism to the feeding behavior integrating neural units by
modulating short term signals that determine meal initiation and
termination as well as energy balance [69]. Two  neurochemically-
distinct populations of hypothalamic neurons located in the arcuate
nucleus (ARC) are critical for the integration of signals of nutri-
tional status, and inﬂuence energy homeostasis [70]. One neuron
group expresses the potent orexigenic neuropeptide NPY and AgRP
and shows high concentrations of binding sites for many hor-pting chemicals and metabolic disorders, Reprod Toxicol (2016),
monal and metabolic signals such as insulin, leptin and ghrelin
[71]. An increase in NPY release results in increased food intake
and decreased energy expenditure. Another set of ARC neurons
expresses the neuropeptide precursor POMC, which is processed
ARTICLE IN PRESSG ModelRTX-7405; No. of Pages 31
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o melanocortin peptides; activation of these neurons decreases
ood intake and increases energy expenditure [72–74]. These two
opulations of neurons thus exert opposite effects on energy intake
nd interact on several levels. The current hypothesis is that as adi-
ose stores increase, both insulin and leptin levels increase along
ith POMC expression, while NPY synthesis and activity are inhib-
ted and food intake is reduced. Conversely, when NPY synthesis
nd release are increased and POMC is decreased, the result is an
ncrease in food intake [75–77]. Dysfunction of the NPY system has
een implicated in obesity and T2D in humans [78,79]
Peptidergic neurons in the ARC project to other hypothala-
ic  nuclei such as the paraventricular nucleus (PVN), dorsomedial
ypothalamus, lateral hypothalamic area (LHA), and perifornical
rea [80,81]. These secondary centers process information regard-
ng energy homeostasis. In particular, the PVN receives NPY/AgRP
nd POMC/METSH/CART projections and contains secondary neu-
ons which are involved, for instance, in emotional and stress
esponses, which have been shown to be physiologically involved in
nergy homeostasis (i.e. thyrotropin releasing hormone (TRH) and
orticoid releasing factor) [82]. In addition, the liver (an important
ntegrator of nutrient metabolism) produces an endocrine satiety
ignal (ﬁbroblast growth factor 21, FGF21), that suppresses the con-
umption of simple sugars, and reduces sweet-seeking behavior, byPlease cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
cting centrally at the level of the PVN [83].
Estradiol, in addition to its function as a gonadal hormone, is
nvolved in the regulation of metabolism through the modula-
ion of food intake, body weight, glucose/insulin balance, bodylance (modiﬁed from Schwartz et al. Nature 404, 661-71, 2000).
fat distribution, lipogenesis and lipolysis, and energy consump-
tion. The central metabolic action of estradiol at the brain level
occurs primarily in the ARC of the hypothalamus where it targets
directly the POMC neurons and indirectly the NPY cells [84]. Estra-
diol represses the synthesis of NPY and AgRP and thereby has an
inhibitory function on food intake [85–88]. Recent data have shown
that leptin and estradiol may  use a common pathway to regulate
energy metabolism, namely the STAT3 pathway in POMC neurons
[87,88].
This integrated pathway between reproductive and metabolic
functions is conﬁrmed by recent ﬁndings on the role of brain
kisspeptin and its receptor KISS1R (reviewed by [89]), originally
identiﬁed based on their endocrine functions of regulating puberty
and fertility, through actions on hypothalamic gonadotropin releas-
ing hormone production [90]. Emerging evidence demonstrates a
signiﬁcant role of kisspeptin for regulating glucose homeostasis,
insulin secretion, as well as food intake and body composition [91],
with deﬁcient kisspeptin signaling resulting in decreased locomo-
tor activity and increased adiposity in a sex-dependent manner
[92]. Organization and function of the kisspeptin-Kiss1R system is
sex-speciﬁc, and sex steroid hormones play a crucial role in deter-
mining such sexual dimorphisms [93,94]. The kisspeptin system is
therefore a potential target of endocrine disruption; in rodent stud-pting chemicals and metabolic disorders, Reprod Toxicol (2016),
ies, exposure to EDCs altered the kisspeptin system in a region-,
sex- and compound −speciﬁc manner, and induced effects on the
timing of pubertal onset, estrous cycles, and socio-sexual behaviors
[95–97].
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.2. Adipose tissue
Adipose tissue is the key regulator of energy balance and nutri-
ional homeostasis and consists of white, brown and beige fat. It
s an endocrine organ with more than 20endocrine, paracrine and
utocrine secretions. The adipose tissue consists of several depots
ocated in subcutaneous, intra-abdominal (visceral) and intra-
horacic areas. Visceral adipose tissue depots are metabolically
ifferent from subcutaneous compartments [98]. Intra-abdominal
visceral) depots are associated with T2D and cardiovascular dis-
ase while subcutaneous depots seem protective against these
iseases [99].
White adipose tissue stores energy as triglyceride and also sig-
als to other organs on the status of energy reserves via hormones,
rowth factors and cytokines [100]. Two major secretions of white
dipose tissue are leptin and adiponectin. Leptin is secreted in
roportion to fat mass; it acts on the brain to reduce food intake
nd increase energy expenditure. However, obese individuals typ-
cally have increased serum leptin levels due to leptin resistance
101]. Adiponectin is also secreted from adipose tissue and induces
atty acid oxidation in liver, improves pancreatic beta cell func-
ion, enhances peripheral insulin sensitivity, suppresses hepatic
lucose production and reduces inﬂammation [102]. Adipose tis-
ue also contains immune cells, from both the adaptive (B and T
ymphocytes) or innate (macrophages) immune system thus it is
n immune organ. Obesity is considered a proinﬂammatory condi-
ion in which both hypertrophied adipoctyes and resident immune
ells produce and release proinﬂammatory cytokines, including IL-
 and TNF, which are associated with chronic low-level systemic
nﬂammation, insulin resistance and T2D. In contrast, in non-obese
ndividuals anti-inﬂammatory cytokines including adiponectin,
nterleukin −10, and transforming growth factor beta (TGFb) are
referentially secreted which, among other functions, improve
nsulin sensitivity [103].
Brown adipose tissue is present throughout life, but with highest
olume in newborns. It generates body heat via non shivering ther-
ogenesis while beige fat appears to be bifunctional, changing to
ither white or brown fat depending on the stimuli [104]. The sym-
athetic nervous system controls lipolysis in white adipose cells
nd stimulates the cold response in brown adipocytes.
In response to excess energy, adipocytes enlarge and/or increase
n number [100]. Excess fat in these cells results in tissue dys-
unction which leads to the development of other diseases and
onditions including inﬂammation, T2D, heart disease, fatty liver,
eproductive problems and some forms of cancer depending some-
hat on the site of the added adipose tissue (e.g. visceral or
ubcutaneous) [100].
In humans, adipose tissue develops by the 14th week of ges-
ation [105] followed by a second period of increased cellularity
hat continues after birth and lasts through adolescence [106]. The
umber of white adipocytes is usually ﬁxed after that time [100]
owever adipocytes are replaced at a rate of about 10% per year in
dulthood [106], thus the tissue is not static. In mice, most sub-
utaneous adipogenesis occurs late in gestation and after birth;
ifferentiation of gonadal fat only appears postnatally between
irth and puberty [107]. Overall, fat mass can continue to grow due
o high fat feeding which induces both hyperplasia and hypertro-
hy in rodents [107] with the hyperplasia occurring in the visceral
issue. Adult mice that are challenged with a high fat diet accumu-
ate fat by hypertrophy in most adipose depots, with the exception
f gonadal (visceral) fat which possesses higher capacity to expand
y hyperplasia [107].Please cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
Speciﬁc genes play critical roles in fat cell development and con-
rol, including PPAR and Runx2, often called the master regulators
f fat cell differentiation [108] and sirtuins which play important
oles in secretion of adipokines including leptin and adiponectin, PRESS
icology xxx (2016) xxx–xxx 5
hepatic glucose metabolism, insulin sensitivity and inﬂammation
[109].
Adipocytes are derived from mesenchymal stem cells (MSCs),
which can be neuroectodermal or mesodermal depending on
where the fat body originates; differentiation of adipocytes
requires a committed pre-adipocyte progenitor [110,111]. Vis-
ceral white adipose tissue (WAT) is primarily derived from the
lateral plate mesoderm [112], brown fat is largely produced by
the paraxial mesoderm [113], and cranial WAT  from the neural
crest [114]. Beige (a.k.a brite) fat arises from WAT  (precursors or
mature cells). Despite this common origin, beige fat is thermo-
genic, like brown fat, so it plays a different metabolic role than
WAT and has a correspondingly different transcriptional program
than WAT  [115,116]. Mesenchymal stem cells harvested from adi-
pose tissue or bone marrow can be made to differentiate into fat,
bone, cartilage, and other lineages in culture [117]; commitment to
each of these lineages is largely mutually exclusive and irreversible
[118]. Transformation of an MSC  into an adipocyte requires initial
commitment to the adipose lineage, followed by terminal differen-
tiation into a mature adipocyte (reviewed in [100,111]). Adipocyte
commitment is mediated by transcription factors Zfp423 [119],
Zfp467 [120], Schnurri2 [121], Tcf7l1 [111] and the mTORC1 effec-
tor S6K1 [122]. Collectively these genes function to sensitize cells
to BMP2/4 signaling while inhibiting canonical Wnt  signaling and
promoting expression of the so-called master regulator of adipo-
genesis, PPAR. Terminal differentiation is primarily controlled by
PPAR and CCAAT-enhancer-binding proteins (C/EBP) −, −, and
− [123,124] which establish a sustained feedback loop. Treatment
of committed pre-adipocytes with an “adipogenic cocktail” (glu-
cocorticoids, cAMP agonists, and insulin) increases expression of
PPAR and C/EBP proteins and is marked by induction of metabolic
genes and adipokines associated with mature adipocytes [124,125].
3.3. Control of glucose homeostasis
Regulation of blood glucose within the normal range is accom-
plished through the concerted action of several organs: glucose
absorption by the intestine, glucose-dependent secretion of insulin
and glucagon from the endocrine pancreas, regulation of glucose
production by the liver, and glucose uptake and metabolism by
peripheral tissues. All these processes are further regulated by the
neural system.
3.4. Pancreas
The endocrine pancreas is comprised of the pancreatic islets
of Langerhans, a heterogeneous population of 1000–3000 cells,
where the predominant cell type is the insulin-releasing -cell.
Other cells include -cells, responsible for glucagon secretion,
and -cells, responsible for somatostatin release, pancreatic
polypeptide-producing cells (PP-cells) and -cells that produce
ghrelin [126,127]. While - and -cell populations represent about
70–80% and 20% respectively of the total islet cell number in
rodents, in humans the pancreas is comprised of 40–45% -cells
and 50% -cells [128] and up to 10% -cells.
The number of -cells rapidly expands in utero and in the neona-
tal period and then replication occurs only at very low levels in
adult rodents [129] and humans [130]. -cells replicate throughout
life after physiologic challenges like high blood sugar, peripheral
insulin resistance and pancreatic injury and their mass is controlled
by insulin, placental lactogen and prolactin (reviewed in [131]).
The liver may  also control -cell proliferation via a novel hormone,pting chemicals and metabolic disorders, Reprod Toxicol (2016),
betatropin [131], which is upregulated in pregnancy and in the
ob/ob and db/db diabetic mouse.
The regulation of blood glucose starts when glucose is taken up
by -cells where it undergoes intermediary metabolism. Insulin
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Fig. 2. Mechanisms of Adipocyte Formation and Sites of Action of Metabolism Disruptors.
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elease takes place after glucose metabolism increases the ATP/ADP
atio, which closes plasma membrane ATP-sensitive K+ (KATP) chan-
els that are responsible for the resting membrane potential. Thislucose and sites of action of metabolism disruptors.pting chemicals and metabolic disorders, Reprod Toxicol (2016),
results in cellular depolarization and ultimately insulin release
from the cell. Insulin secreted into circulation then binds to recep-
tors on the surface of target cells in the periphery to facilitate
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lucose uptake and metabolism. Impaired -cell insulin production
esults in a rise in blood glucose levels that over time can lead to
he development of diabetes (See Fig. 3). This metabolic transition
an arise from frank -cell destruction as seen in type 1 diabetes
r to -cell dysfunction arising from increased synthetic demand
esulting from peripheral insulin resistance as in T2D.
Glucagon is another key glucose-regulating hormone. It is
ecreted by -cells in response to falling blood glucose levels
nd principally stimulates the liver to increase glycogenolysis
nd gluconeogenesis to raise circulating blood sugar [132,133].
hen extracellular glucose concentrations rise to levels required
or insulin release, glucagon release decreases [134]. Several
aracrine and neural mechanisms also inhibit glucagon release
127,135–138]. While pure hyperglucagonemia is a rare cause of
iabetes, disruptions in the autoregulatory feedback loop linking
nsulin and glucagon secretion is thought to result in inappropriate
lucagon secretion in both type 1 and T2D [139].
.4.1. Liver
The liver is the principal location of glucose storage as glycogen,
nd the main source of glucose for all tissues. Because the pan-
reatic veins drain into the portal venous system, every hormone
ecreted by the pancreas must traverse the liver before enter-
ng systemic circulation. The liver is a major target for pancreatic
nsulin and glucagon action as well as their site of degradation. In
act, 70% of hepatic glucose output occurs via liver glycogenolysis
nd 30% via gluconeogenesis.
Insulin promotes glycogen synthesis and decreases its break-
own after enhancing the transcription of glucokinase and the
ctivation of glycogen synthase through changes in its phosphory-
ation state. Insulin increases transcription of the glucokinase gene
nd other enzymes involved in glycolysis such as phosphofructok-
nase and pyruvate kinase, promoting glycolysis [140]. Insulin also
nhibits gluconeogenesis by decreasing phosphoenolpyruvate car-
oxykinase (PEPCK) and fructose-1, 6-biphosphatase (FBPase) gene
xpression. As a result, insulin inhibits glucose production during
he fed state, keeping glucose levels within the normal range. At
he same time, high glucose levels inhibit glucose-6-phosphatase
nd decrease the activity of glycogen phosphorylase; all together,
hese processes considerably reduce the conversion of glycogen to
lucose.
Insulin also promotes the storage of fat by stimulating lipogen-
sis. It inhibits the oxidation of fatty acids by decreasing fatty acid
ransport into the mitochondria. Additionally, insulin stimulates
atty acid synthase (FAS). All together, these pathways promote the
ormation of triglycerides that can either be stored in the liver or
xported as very low density-lipoproteins (VLDL).
On the other hand, glucagon signaling in the liver plays a key
ole during fasting, as well as in the adaptive response to hypo-
lycemia. After binding at its receptors, glucagon activates the
AMP/PKA pathway, which decreases glycolysis via a modulatory
ction on pyruvate kinase [127]. Glucagon increases gluconeo-
enesis after up-regulation of glucose-6-phosphatase and PEPCK
hrough the activation of coactivators such as CREB-binding protein
CBP), P300, PGC-1 and TORC2 [134,141–144]. In addition, glucagon
lso activates ketogenesis. All these effects favor hepatic release
f glucose to maintain normal blood glucose levels during fasting.
lucagon also promotes the oxidation of fat in the liver, increas-
ng the activity of the citric acid cycle and the generation of ketone
odies. Moreover, there is a glucagon-induced decrease of triglyc-
ride, VLDL, cholesterol and fatty acid synthesis mediated by PPAR
145].Please cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
.4.2. Skeletal muscle
Skeletal muscle is the major site of insulin-mediated glucose
sage; it can clear up to 70% of the blood glucose pool. Unlike PRESS
icology xxx (2016) xxx–xxx 7
the liver, glucose transport in skeletal muscle is insulin depen-
dent via the recruitment of the glucose transporter GLUT4 to the
membrane. Insulin activation of hexokinase and glycogen synthase
enhances glycogen synthesis. Activation of phosphofructokinase
and pyruvate dehydrogenase enhances glucose breakdown and
oxidation. The action of insulin in glucose utilization allows the
muscle to store fat as triglycerides that together with glycogen
can be used as sources of energy during exercise and heat gen-
eration.
3.4.3. White adipose tissue
Similar to skeletal muscle, insulin promotes recruitment of
GLUT4 to the membrane and accelerates glucose transport into
adipocytes. It then induces the breakdown of glucose to gener-
ate triglycerides. These triglycerides are stored in fat together with
those delivered via the circulation as chylomicrons and VLDL. In
addition, insulin inhibition of triglyceride lipase decreases triglyc-
eride breakdown. Insulin decreases lipolysis through inhibition of
hormone sensitive lipase in a cAMP-dependent manner [146,147].
Insulin promotes the synthesis of lipoprotein lipase (LPL), which is
exported to the endothelial cell plasma membrane. Once anchored
there, LPL cleaves triglycerides from VLDL and chylomicrons into
glycerol and fatty acids that are taken up by nearby adipocytes to
form triglycerides.
Although the role of glucagon in WAT  is controversial, recent
results point to a role in lipolysis [127]. This lipolytic action has
been attributed to glucagon-induced release of ﬁbroblast growth
factor 21 (FGF21) [148] as well as to signals from the sympathetic
nervous system [149].
3.5. Importance of insulin resistance
Insulin resistance is present in many cases of obesity and T2D.
However, most insulin-resistant individuals do not develop hyper-
glycemia due to compensatory increases biosynthesis and the
release of insulin as well as increases in pancreatic -cell mass.
For example, obese subjects secrete 2–5 times more insulin in
response to glucose, while athletes secrete 2–5 times less insulin
[150]. Insulin resistance developed during puberty and pregnancy
is counteracted by adaptation of -cell mass and function, with sex
and maternal hormones playing important roles [151–155]. Insulin
sensitivity, therefore, regulates -cell function; insulin resistant
subjects, whether they are obese or lean, have greater insulin
response and lower insulin clearance than insulin-sensitive indi-
viduals. In order for insulin resistance to lead to T2D, -cells
adaptation must fail [156]. Regulation of -cell mass may  occur
by hypertrophy of existing cells and proliferation. Glucose, non-
esteriﬁed fatty acids, incretins, and neuronal signaling are involved
in increasing -cell mass and function, yet when glucose and lipids
are increased for longer than normal -cell are killed which gener-
ates the onset of T2D [157,158].
The ability of pancreatic -cells to integrate responses to
changes in insulin sensitivity likely involves increased metabolism
and metabolic signals. These include signaling molecules from
adipocytes (e.g. NEFAs signaling via GPR40) as well as and fatty acyl-
CoAs that augment insulin release via the exocytotic machinery and
protein kinase C (PKC). Leptin, adiponectin, and proinﬂammatory
cytokines such as TNF, IL-6 and monocyte chemoattractant pro-
tein (MCP-1) from macrophages and other cells inﬁltrating adipose
tissue have a role as well [157]. Pancreatic -cells are responsible
for glucagon production and release. Thus alterations in the pancre-pting chemicals and metabolic disorders, Reprod Toxicol (2016),
atic -cell function can also contribute to T2D [127]. Unlike -cells,
the mass of pancreatic -cell does not decrease in T2D, resulting in
an increased -to- cell ratio; this altered ratio also contributes to
higher plasma levels of glucagon and therefore to hypoglycemia.
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Thus, when -cells are healthy, their adaptive responses
ounterbalance insulin resistance and preserve normal glucose tol-
rance. However, if -cell dysfunction occurs due to genetic causes,
nvironmental perturbations, or both, then the individual is more
rone to develop impaired glucose tolerance, high fasting glucose
evels, and ultimately T2D.
.6. Liver control of xenobiotic and intermediary metabolism
The liver is the largest and most metabolically complex organ in
he human body. Hepatocytes make up over 80% of total liver mass
nd play a critical role in intermediary energy (lipid, carbohydrate,
mino acid) and xenobiotic metabolism (Phase I–III metaboliz-
ng enzymes). Other liver-speciﬁc cell types include Kupffer cells,
iliary epithelial cells, sinusoidal endothelial cells, and stellate
ells. These cells have specialized functions ranging from protec-
ion against infection, bile duct ﬂow, endocytosis and ﬁbrosis. The
iver arises from the hepatic diverticulum of the foregut during the
ourth week of gestation. Hepatoblasts are bipotential progenitor
ells arising from foregut endodermal cells that differentiate into
epatocytes and cholangiocytes.
The liver is the principal organ for xenobiotic detoxiﬁcation.
igand-activated xenobiotic receptors induce foreign compound
etabolism by cytochrome P450s. For example, the aryl hydrocar-
on receptor (AhR) induces expression of CYP1A1, the constitutive
ndrostane receptor (CAR) induces CYP2B10, and the pregnane X
eceptor (PXR) induces CYP3A4. In general, chemical ligands are
etabolized by the P450 s that they induce. In addition to foreign
ompound metabolism, xenobiotic receptors play an important
ole in the control of hepatic lipid and carbohydrate metabolism.
t was recently proposed that activation and cross-talk of xeno-
iotic receptors by foreign compounds is a molecular initiating
vent in hepatic steatosis [159]. Likewise, interactions between
nvironmental compounds and xenobiotic receptors regulate, in
art, hepatic carbohydrate metabolism including gluconeogene-
is and insulin resistance [160,161]. These mechanisms appear to
ccount for the wasting syndrome associated with some dioxin-like
hemicals that activate the AhR [161].
Owing to its critical role in xenobiotic and intermediary
etabolism, the liver is a principle target organ for chemicals
esulting in the development of steatosis. Steatosis may  progress
o steatohepatitis (steatosis with superimposed hepatic inﬂam-
ation), cirrhosis and hepatocellular carcinoma, and ultimately
iver-related death if liver transplantation does not occur. In the
linic, steatohepatitis is named according to its etiology: alcohol
alcoholic steatohepatitis, ASH), cancer medications (chemother-
py associated steatohepatitis, CASH), excess dietary lipids or
arbohydrates (NASH), and industrial chemicals (toxicant associ-
ted steatohepatitis, TASH) [162,163]. While disease mechanisms
ary by etiology [164], steatosis is invariable associated with an
mbalance of hepatocyte lipid synthesis, oxidation, uptake, and
fﬂux via VLDL [159].
.7. Thyroid control of metabolism
The thyroid gland, located in the neck, is one of the largest
ndocrine glands in the body. It plays a crucial role in normal
rowth and development, energy homeostasis and regulation of
dult metabolism. The main hormones secreted by the gland are
hyroxine (T4), which has limited biological activity and triiodothy-
onine (T3) which is more potent but with a shorter half-life. T4 isPlease cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
onverted to T3 by the enzyme thyroxine 5′-deiodinase [165]. Thy-
oid hormones are regulated by thyroid stimulating hormone (TSH)
ecreted by the anterior pituitary gland, which in turn is regulated
y TRH produced by the hypothalamus [166,167]. PRESS
icology xxx (2016) xxx–xxx
Tight interaction exists between thyroid function, weight con-
trol, and obesity [168]. Mild differences in thyroid function can be
associated with changes in body weight and fat mass [168,169].
Even small variations in serum TSH, within the reference range of
the assay, were associated with differences in body mass; higher
levels of TSH were associated with increased BMI  [170–172]. There
is an inverse correlation between free thyroxine (fT4) values and
body mass index (BMI), even when fT4 values remain in the normal
range [173,174].
3.8. Sexual dimorphism and metabolism
In humans, there are important sex differences in the incidence
and health consequences of obesity; men  and women differ in the
patterns of fat deposition, fat mobilization, utilization of fat, and
the consequences of both excess and insufﬁcient fat stores. Gonadal
hormones appear to play a crucial role in shaping such differences.
Women suffer fewer obesity-related disorders than men  do. In fact
women are resistant to free fatty acid-induced insulin release and
are therefore less prone to T2D before menopause but the preva-
lence of these disorders increases dramatically after menopause
[175]. The prevalence of T2D is higher in men  before puberty com-
pared to reproductive age females. It is noteworthy that T1D has a
male predominance as well [176]. Androgens, adiposity and disease
are clearly interrelated in humans.
These asymmetries in energy balance traits probably reﬂect
evolved adaptive differences due to differential investment and
costs of reproduction in male and female mammals and are mainly
shaped by gonadal hormones either during development (organiza-
tional effects) or at adulthood (activational effects) (for reviews see
[177–179]). Development and maturation of brain circuits involved
in the regulation of food intake and metabolism occur during the
perinatal period. The current literature argues that there are mul-
tiple critical periods in which hormones organize energy balancing
traits; besides the fetal and neonatal stage, the peripubertal period
is also a time window when sexually dimorphic eating behaviors
are established [180]. Sex differences in body fat composition and
distribution, energy expenditure, orosensory physiology, taste and
smell preference, food intake, binge eating, susceptibility to diet
induced obesity, responses to leptin-, ghrelin,- or insulin- induced
hyperphagia, POMC gene expression in the ARC nucleus, and many
other traits are well documented (reviewed in: [181–183]).
The POMC, melanocortin system, is sexually dimorphic [184].
In adults, females have increased responsiveness to leptin and
decreased responsiveness to insulin in comparison to males. These
differences are estrogen dependent [185], and they are perina-
tally organized by testosterone [186]. The NPY/AgRP circuit is
also sexually dimorphic. In particular, in situ hybridization studies
demonstrated sex differences in the distribution of NPY mRNA-
containing cells in the rat ARC, and its modulation by testosterone
in males [187]. Also, NPY immunoreactivity is sexually dimorphic
in the ARC, the dorsomedial hypothalamus, and the PVN [188];
NPY-Y1 receptor expression is higher in females compared to males
[189].
Male mice have higher levels of daily food intake, post-fast
hyperphagia and leptin-induced hypophagia compared to female
mice, and these behavioral differences are related to sexual dimor-
phisms in the ARC as far as the number of ARC cells containing NPY,
AgRP, and POMC. Females perinatally treated with testosterone or
DHT show male-like levels of food intake, post-fast hyperphagia
and POMC gene expression and projection [186].
Estrogens play a pivotal role in regulating energy homeostasis,pting chemicals and metabolic disorders, Reprod Toxicol (2016),
especially in female mammals, either by acting directly on the brain
or through activation of estrogen receptors (ER) on adipocytes.
Estrogens protect against increased adiposity/obesity through their
effects of suppressing appetite and increasing energy expenditure;
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stradiol suppresses feeding by enhancing the potency of other
norectic signals (leptin, apolipoprotein, BDNF, cholecystokinin)
nd by decreasing the potency of orexigenic signals such as ghrelin
nd melanin concentrating hormone [87,185,190,191]. The liver is a
ajor target for estrogen action in female mammals and the activity
f the liver ER is strictly associated with ovarian activity [192]. In
he liver, ER regulates fertility in response to protein consumption
nd controls lipid and cholesterol synthesis in relation to the repro-
uctive cycle [193]. Since the liver is the major organ for the control
f energy homeostasis, the activity of hepatic ER also inﬂuences
he synthesis and secretion of the signaling molecules necessary for
oordinated responses among liver, fat, muscles and brain [192].
In mammals, including humans, the liver is a sexually dimor-
hic organ and exhibits major differences in the proﬁle of steroid,
ipid, foreign compound metabolism [194], and gene expression.
hese differentially expressed genes regulate a wide range of bio-
ogical processes; accordingly, many enzymes, such as steroid
ydroxylases belonging to the cytochrome P450 (CYP) superfam-
ly, are expressed in the liver in unique, sexually biased patterns
195]. Such differences have implications for sex-related steroid
etabolism, xenobiotic metabolism and pharmacokinetics, and
ifferential susceptibility to some liver diseases [23,196]. The
exual dimorphism of liver gene expression is established and
aintained, in part, by the temporal pattern of pituitary GH secre-
ion, which is sex speciﬁc in many species (episodic in males
nd more stable in females) [197]. GH secretion is affected by
rain and lactotrope dopamine 2 receptors (D2Rs) [198]. A link
xists between obesity, growth, and dopaminergic systems located
ithin the central nervous system and in other tissues [199–201].
. Environmental contributions to obesity, T2D, and
yslipidemia
The global pandemic of obesity, T2D and MetS is often causally
inked to marked changes in diet and lifestyle, namely increases
n dietary intake of high energy diets and concomitant reduction
n physical activity levels [202]. However, it is clear that the sus-
eptibility to these diseases is not that simple. Indeed there have
een multiple environmental factors that have been linked to the
ncrease in these metabolic diseases including stress, lack of sleep,
denoviruses, childhood antibiotics [202–205] and exposure to
nvironmental chemicals [206]. While all of these environmen-
al stressors likely play some role in the epidemic of metabolic
iseases, we  focus here on exposure to environmental chemicals,
specially EDCs and the role they might play in disease etiol-
gy. Indeed, the current rise in metabolic diseases correlates with
ubstantial increases in environmental chemical production and
xposures over the past four decades [207–209].
.1. Overview of endocrine disrupting chemicals
In 2012, the Endocrine Society deﬁned EDCs as “an exogenous
hemical, or mixture of chemicals, that can interfere with any
spect of hormone action” [210]. This deﬁnition is a more simpliﬁed
ersion of the one originally proposed by the US EPA, that EDCs are
an exogenous agent that interferes with the production, release,
ransport, metabolism, binding, action, or elimination of natural
ormones in the body responsible for the maintenance of homeo-
tasis and the regulation of developmental processes” [211]. At the
lobal level, the WHO/UNEP deﬁnition of EDCs is “an exogenous
ubstance or mixture that alters the function(s) of the endocrinePlease cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
ystem and consequently causes adverse effects in intact organ-
sm, or its progeny or (sub) population [212]. Although EDCs were
rst identiﬁed as agonists or antagonists of estrogen, androgen and
hyroid hormone receptors [213], EDCs disrupt hormonal signal- PRESS
icology xxx (2016) xxx–xxx 9
ing systems by interfering with a variety of hormones through
numerous mechanisms. EDCs can disrupt normal hormone levels
by inhibiting or stimulating the production and metabolism of hor-
mones, or changing the way hormones are transported to target
tissues.
The effects of EDCs, like those of hormones, can occur at very
low levels [214–217]. Other principles of hormone action are simi-
larly expected for EDCs including their ability to induce tissue- and
time-dependent effects and strong evidence that responses to EDCs
can be non-monotonic (often referred to as biphasic or U-shaped
responses) [5,210,215,218,219]. Some EDCs are persistent and can
bioaccumulate in tissues [220,221]. With more than 85,000 regis-
tered chemicals in commerce, most of which are poorly studied;
current estimates have identiﬁed approximately 1000 chemicals
that meet the criteria of an EDC [213,222].
Decades of work from both basic and clinical endocrinology
have revealed that the disruption of hormones can have detri-
mental effects on a variety of diseases [223] [223,224]. A number
of recent “state of science” reviews of the EDC literature, as well
as large reviews of hundreds or thousands of EDC studies, draw
strong conclusions about the association between EDC exposures
and diseases [210,215,218,223,225–228]. These conclusions are
drawn from observational human epidemiology studies and con-
trolled laboratory animal studies, as well as additional support from
wildlife studies, in vitro mechanistic studies, and in silico studies. In
2015, a review of the EDC literature by scientists in the Endocrine
Society found that there was strong evidence for a role of EDCs in the
etiology of metabolic diseases, although these diseases were gener-
ally examined individually [229]. Some of these conclusions were
challenged, with groups contesting the strength of evidence linking
EDC exposures to endocrine-related diseases [230–235]. However,
whereas some useful criticisms were put forward, these challenges
typically resulted from a lack of understanding of the endocrine sys-
tem, as well as of endocrine disruption as an effect on a complex
regulatory network of the organism [219,236–241]. On the con-
trary, the need to fully appreciate the impact of EDCs is apparent
considering the health care costs associated with inaction [9,228].
A number of relevant factors can inﬂuence whether signiﬁcant
effects are observed in experimental studies of EDCs and these
factors can affect the strength of the evidence for an effect. First,
measurement of body weight alone is now recognized to be an
inadequate measure in experimental rodent studies to assess the
effects of chemical exposure on adipocyte endpoints [242]. Second,
the endocrine milieu of males and females is different, and thus
it should be expected that sex-speciﬁc effects are often observed
because of EDC exposure, particularly for compounds that interfere
with sex hormones. Third, the speciﬁc type of feed used in animal
experiments can affect sex hormone levels in pregnant females
and fetuses, and consequently result in signiﬁcant differences in
phenotype, including the potential to modify effects of chemical
exposures [243,244]. Indeed, natural diet components and EDCs
may  interact in several ways [245].
One relevant challenge concerns the publication of apparently
“conﬂicting” results on EDCs. Independent replication of results is
the accepted standard for assessing validity of ﬁndings in research,
thus the issue of non-replication of ﬁndings in some EDC stud-
ies must take into account the issues described above (sensitivity
of endpoint, sex-speciﬁc effects, inﬂuence of animal feed), as well
as the appropriate use of positive controls [246–248,249], and/or
negative control groups [250,251], and the range of dose levels
used [219,252]. There also appears to be a relationship between
the source of funding and the likelihood of identifying effects ofpting chemicals and metabolic disorders, Reprod Toxicol (2016),
EDCs [237,248,253]. Thus, rather than labelling results as “conﬂict-
ing” the factors involved in the apparent failure to replicate certain
ﬁndings should be assessed [246,254].
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.2. EDC exposures: sources & routes
As noted above, approximately 1000 chemicals have been
dentiﬁed that meet the criteria of an EDC [213,222]. These
ompounds are used in a wide range of consumer products
ncluding food packaging, building materials, pesticides, cloth-
ng and upholstery, personal care products, detergents and other
leaning agents, thermal paper, plastics and medical equipment
210,215,226,227,255,256]. Some chemicals used in industrial pro-
esses lead to unintended contamination of food, water and air.
hus, routes of exposure can include oral, dermal, and inhalation,
s well as subcutaneous and intravenous (via medical equipment).
The US CDC’s National Health and Nutrition Examination Survey
NHANES) is a nationally representative biomonitoring program
hich assesses, among other things, exposures to environmental
hemicals in the general population [257].The CDC has documented
idespread exposures to a number of EDCs (e.g. [258–263]). Impor-
antly, a large number of chemicals are not examined, and thus
he number of exposed individuals, as well as the typical levels of
xposure, remains unknown. Although the sampling of infants and
oung children is limited in the context of NHANES [264], other
tudies have revealed the presence of environmental chemicals
n placenta, amniotic ﬂuid and umbilical cord blood, document-
ng exposure throughout the most critical stages of development
s well as across the lifespan (e.g. [265–271]).
.3. Vulnerable windows of exposure and metabolic disorders
The concept that adult diseases could have a fetal basis was high-
ighted by the work of David Barker who proposed a hypothesis,
hich was expanded to the Fetal Basis of Adult Disease and has
ow been restated as the Developmental Origins of Health and Dis-
ase (DOHaD) hypothesis [272–274]. The core DOHaD hypothesis
s that there are critical windows during development, and envi-
onmental disruptions during these life stages can lead to subtle
hanges in gene expression, tissue organization, or other levels of
iological organization that lead to permanent dysfunction lead-
ng to increased susceptibility to disease. Unlike birth defects and
eonatal diseases, these dysfunctions manifest later in life mostly
s increased vulnerability to common diseases including obesity
275–277]. Barker and others showed that low birth weight (LBW)
abies resulting from maternal malnutrition developed increased
usceptibility to diseases in adult life including coronary heart dis-
ase, obesity, stroke, T2D, osteoporosis, increased blood pressure,
yslipidemia, impaired glucose metabolism and metabolic dys-
unction (reviewed in [273,278]).
Barker’s focus on nutrition was preceded by the iatrogenic event
nvolving the prescription of diethylstilbestrol (DES) to millions of
omen from the 1940s through the early 1970s to prevent mis-
arriage. Not only was DES shown to be ineffective, it increased
he incidence of a rare cervical cancer. Animal studies conﬁrmed
t is a transplacental carcinogen and the effects, including other
eformities of the reproductive tract and increased incidence of
ammary cancer, shown to result from developmental exposure
n animal models, have now been conﬁrmed in human studies.
he DES tragedy remains one of the best examples of the long-
atency adverse health outcomes associated with fetal endocrine
isruption and was a clear example of DOHaD, with adverse health
utcomes associated with the alteration of normal endocrine func-
ion during development [279,280].
The observation that alternations in human development affects
he risk of non-communicable diseases later in life is conﬁrmed byPlease cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
pidemiology studies focusing on both nutrition and environmen-
al chemical exposures [276,281–283]. Developing organisms are
xtremely sensitive to perturbation by chemicals including EDCs
ecause hormones and growth factors control development. Alter- PRESS
icology xxx (2016) xxx–xxx
ations of their levels during development by EDCs leads to tissues
with abnormal gene expression, numbers of cells, location of cells,
imbalance between cell types, as well as altered organ structure
and hormonal signaling that lead to increased susceptibility to dis-
ease/dysfunctions across the life course [281,284]. Adverse effects
may be most pronounced in the developing organism and occur at
concentrations of the chemical that are far below levels that would
be considered harmful in the adult [285,286]. Some of the reasons
for this increased sensitivity include the fact that the protective
mechanisms that are available to the adult, such as DNA repair
mechanisms, a competent immune system, detoxifying enzymes,
liver metabolism, and the blood/brain barrier are not fully func-
tional in the fetus or newborn. In addition, the developing organism
has an increased metabolic rate as compared to an adult, which, in
some cases, may  result in increased toxicity [286].
Another critically important reason for the increased sensitiv-
ity of the developmental period to EDCs (as well as nutritional
deﬁcits) is that epigenetic signaling regulates gene expression
which controls development. Epigenetic changes provide biochem-
ical evidence of the deleterious effects of adverse conditions during
development and subsequent disease including metabolic diseases
[287]. Some aspects of epigenetic signaling (e.g.DNA methylation,
histone marks, chromatin remodeling and noncoding RNAs) are
likely involved in the mechanisms responsible for altered program-
ming of tissue development by EDCs that lead to obesity [288–290].
Since hormones and growth factors control development, signal-
ing errors caused by hormones expressed at the wrong time or
concentration can cause alterations in gene expression in tissues,
and these abnormal expression patterns become permanent due to
epigenetic signaling [290–292].
There are now credible data that supporting the claim that many
chronic diseases including obesity, T2D and MetS can be linked to
epigenetic changes in cells and tissues during development that
manifest in altered tissue development as a result of early environ-
mental factors (stress, drugs, nutrition, environmental chemicals)
[293–295]. Extensive data from animal and human studies show
that developmentally induced disease outcomes often are not
immediately apparent but manifest later in life [277,296,297].
There are now data that show that environmental factors can
account for disruption of individual or multiple systems involved
in metabolism depending on the timing of exposure. For example,
exposure to a chemical during the fetal or perinatal period can per-
manently alter the functioning of mesenchymal stem cells and lead
to disruption of adipocyte function [298]. Altered adipocyte func-
tion is likely to affect other organs/tissues due to hormonal and
paracrine action. This brief chemical exposure might also impact
differentiation of the pancreas, heart, brain, liver or any other com-
ponent of the complex regulatory system impacting the various
components of metabolic disease [275].
4.4. Obesogen hypothesis overview (historical)
In 2002, Baille-Hamilton wrote the ﬁrst article relating envi-
ronmental chemicals to obesity. Her article, “Chemical toxins: a
hypothesis to explain the global obesity epidemic”, suggested that
the current obesity epidemic was  associated with the increase
in production of environmental chemicals [299]. She reviewed
published studies showing associations between exposure to a
variety of environmental chemicals, including some pesticides, sol-
vents, plastics, ﬂame retardants and heavy metals, and increased
weight gain; because these studies originally focused on weight
loss and toxicity, their effects on weight gain had gone unnoticed.pting chemicals and metabolic disorders, Reprod Toxicol (2016),
In 2006, Grun and Blumberg, published their now classic paper, in
which they coined the term “obesogen” followed by a 2009 review
“Endocrine disruptors as obesogens” [300]. They noted the exis-
tence of chemicals that alter regulation of energy balance to favor
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eight gain and obesity and proposed that obesogens derail the
omeostatic and reward mechanisms important for weight con-
rol, such that exposed individuals have increased susceptibility to
eight gain despite normal diet and exercise.
The obesogen hypothesis makes two important points. First,
usceptibility to obesity starts during development (in utero and
he ﬁrst few years of life). Second, susceptibility to obesity is due in
art to the inﬂuence of a speciﬁc subclass of EDCs that alter devel-
pmental programming, and thus disrupt the set point for weight
ain later in life.
“Obesogens” are deﬁned functionally as chemicals that promote
besity by increasing the number of fat cells and/or the storage of
at in existing adipocytes. Obesogens can also act indirectly to pro-
ote obesity by shifting energy balance to favor calorie storage, by
ltering basal metabolic rate, by altering gut microbiota to promote
ood storage [301], and by altering hormonal control of appetite and
atiety [298,302–305]. New obesogenic chemicals are being identi-
ed at an increasing rate. The obesogen ﬁeld has recently expanded
o include chemicals that cause or lead to diabetes [306] as well as
ltered lipid metabolism and fatty liver [307].
.5. The metabolism disrupting chemical (MDC) hypothesis
In 2015 the Parma Consensus Statement proposed that the
besogen hypothesis should be expanded, considering newer evi-
ence of chemicals that increased susceptibility to T2D, liver lipid
bnormalities and MetS [308]. The Parma Statement proposed a
ame change to ‘metabolic disruptor hypothesis’, which we fur-
her propose should be termed ‘metabolism disrupting chemical
MDC) hypothesis’ to distinguish the role of chemicals from other
etabolic disruptors such as nutrition and stress. The MDC  hypoth-
sis postulates that environmental chemicals have the ability to
romote metabolic changes that can result in obesity, T2D or fatty
iver in animals including humans; these metabolic alterations may
lay an important role in the global epidemics of obesity, T2D and
etS. In the study of liver disease etiology, the MDC  hypothesis pro-
ides, for the ﬁrst time, a framework for the integration of different
tiology of steatohepatitis (ASH, CASH, NASH, and TASH). Alco-
ol, chemotherapeutic medications, fructose, dietary fatty acids,
nd industrial chemicals are all MDCs; while they disrupt hep-
tic metabolism differently the pathologic end result is the same
162,163].
For the remainder of this manuscript we will focus on MDCs as
hemicals that can alter any aspect of metabolism and describe the
urrent state of the science.
. MDCs and metabolism-relevant diseases
.1. Adipogenesis, subsequent weight gain and obesity
A number of MDCs have been shown to signiﬁcantly alter the
unction (gene expression, hormone secretion) of white adipose
issue, adipose tissue mass (adipocyte number and/or volume),
r body weight in animal models after developmental exposures
Fig. 2). Epidemiological studies also support the identiﬁcation of
besogenic MDCs [309,310] and these studies focus mainly on
eight gain and (body mass index) BMI  as endpoints. This is typ-
cal for a new ﬁeld, where the focus is on descriptive studies that
how that a chemical can have an effect on an endpoint or disease of
nterest (e.g. weight gain). In many cases, effects of MDCs on adult
diposity and/or body weight are reported to be signiﬁcant for onlyPlease cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
ne sex, consistent with the sexually dimorphic responses that are
 common feature of EDCs and thus MDCs [226].
Nicotine is an MDC  where there are compelling data for its
besogenic properties from both animals and human studies PRESS
icology xxx (2016) xxx–xxx 11
[7,311,312]. Maternal smoking in pregnancy is a risk factor for sub-
sequent obesity in offspring [313] even when exposure is limited
only to early pregnancy [314,315]. Although multiple mechanisms
have been proposed, associations may  be partly attributable to
impaired fetal growth, which as Barker and colleagues noted is
a risk factor for subsequent rapid growth and long-term obesity
[316].
Developmental exposure in mice to DES [317] has also been
shown to increase weight gain which is speciﬁc to females and does
not appear until puberty [318]. In another study, prenatal expo-
sure to DES resulted in an increase in number of adipocytes in the
gonadal fat pad of male mice[319]. Two  epidemiological studies
also link DES exposure to obesity; prenatal exposure to DES is asso-
ciated with an increased likelihood of childhood obesity at age 7y
[320] and increased risk of adult obesity in women that was most
evident at lower doses [321].
Bisphenol A (BPA) [322–324], a chemical used to make poly-
carbonate plastic, epoxy resins that line food and beverage cans,
and as a developer in cash register receipts has been shown to
increase weight gain and body fat after developmental exposure
in rats [325–327] and mice [319,328–330]. Some studies have not
shown effects of BPA on weight gain [97,331] including government
standardized study designs e.g. guideline studies, [332,333]. The
two guideline studies with CD-SD rats, which appear to be relatively
insensitive to xenoestrogens [334], showed no signiﬁcant effects for
any outcome measure. Also in one mouse study reporting no signif-
icant effect of BPA on body fat[331], the control animals were obese
due to the use of casein-based feed, which increases body fat in CD-
1 mice [335,336]. These studies differ with regard to several aspects
including animal strain, doses, developmental windows, and diet
which are likely responsible for the discordant results (reviewed in
[337]). Also a distinction needs to be made between studies that
only measured body weight (for example [329]) which is recog-
nized to be a poor indicator of signiﬁcant changes in body fat in
rodents [7] and studies that actually measured body fat.
Human studies have shown that prenatal exposure to BPA was
associated with increased body fat at age 7 [338] or BMI  by age
9 [339] or accelerated postnatal growth without a change in BMI
between age 2–5 [340] consistent with the DOHaD prediction that
light at birth babies would experience increased rate of growth
in childhood[14,341]. Not all epidemiology studies report a pos-
itive relationship between an exposure and a health outcome
[339,340,342–344] which is not uncommon for studies linking
environmental chemicals with adverse outcomes in humans, pos-
sibly due to potential for multiple environmental “stressors” to
interact with chemical exposures [342,345,346]. Because of con-
siderable within-person variability [347–350] and because most
studies typically have only one sample to characterize exposure,
BPA exposures may  have been substantially misclassiﬁed and peak
exposures, which generally occur in the evening, may  have been
underestimated [348]; these misclassiﬁcations may  have increased
the likelihood of a false negative outcome. Stronger attention is also
needed for potential confounding by diet, which is only one source
of BPA exposure [256,351]. Moreover, since the developing organ-
ism is more susceptible to BPA effects, epidemiology studies must
consider the lifestage when exposure is measured. The inconsisten-
cies in the data notwithstanding, there are data from both animal
and human studies that support the hypothesis that developmen-
tal exposure to BPA can lead to an increase in weight gain later in
life in exposed offspring.
Phthalates are a class of chemicals that promote ﬂexibility
in plastic products such as tubing and vinyl ﬂooring. Fragrancespting chemicals and metabolic disorders, Reprod Toxicol (2016),
and a variety of household and personal care products includ-
ing food packaging also contain a variety of phthalates. Phthalate
metabolites have been shown to activate PPAR receptors and have
antiandrogenic effects which may  contribute to the development
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f obesity [352]. Prenatal exposure of mice to one phthalate, DEHP,
esults in increased body weight as well as increased body fat in
ale offspring; similar ﬁndings were reported in studies from dif-
erent labs using different animal models [353–356]. Epidemiologic
ata linking prenatal phthalate exposures to obesity are limited
nd mixed [357–361]. Although daily exposure measurements are
ess variable than BPA, phthalates are also prone to exposure mis-
lassiﬁcations. One recent study found evidence of a sex-speciﬁc
ffect, with high molecular weight phthalates — including DEHP —
ssociated with reduced BMI  z-scores among boys, but increased
MI  z-scores among girls from Spain [359]. DEHP metabolites were
ssociated with lower BMI  z-scores in ethnically diverse boys from
 US cohort [357], and in children of both sexes in another [358].
owever, high molecular weight phthalates were associated with
igher BMI  z-scores in US children of Mexican American and African
merican descent, though not in Whites [362]. Phthalate exposure
uring pregnancy was also associated with increased triglyceride
evels in cord blood and with increased body mass three months
fter birth in boys [363]. While more data are needed, these data
upport the conclusion that developmental exposure to DEHP and
erhaps other phthalates, depending on their molecular weight,
an lead to increased weight gain in animal and human studies.
Tributyltin (TBT) [364,365] is an organotin used as a fungi-
ide; it is a retinoic acid X receptor and PPAR agonist. Several
aboratories have shown that TBT stimulates adipogenesis in
readipoctyes in vitro [366–368,369]. Prenatal exposure to TBT
esults in increased lipid accumulation, increased adipose tissue
ass (due to both adipocyte hyperplasia and hypertrophy), and
educed muscle mass that persists into adulthood and across gen-
rations in mouse models [307,364] and increased adiposity in
ebraﬁsh [370]. A recent study explored organotins and weight gain
n humans for the ﬁrst time, ﬁnding placental TBT to be associated
ith a non-signiﬁcant trend towards higher weight gain, but only
n the ﬁrst three months of life [371]. These limited data in humans
arrant further investigation, whereas the animal data strongly
upport the notion that TBT exposure during development may  play
 role in the obesity epidemic.
Polycyclic aromatic hydrocarbons (PAHs) are a family of envi-
onmental chemicals that are byproducts of fossil fuel burning
hich includes diesel exhaust, air pollution and cigarette smoke
206]. Prenatal exposure to a nebulized PAH mixture 5 days a
eek for three weeks led to increased weight, fat mass and higher
ene expression of PPAR, fatty acid synthase and adiponectin
n mice[372]. Developmental exposure in rats to PAHs in diesel
xhaust have been shown to lead to increased obesity, insulin resis-
ance and inﬂammation; these effects were observed only in adults
ed a high fat diet, indicating a second hit was needed, and only
n males, indicating a sexually dimorphic effect [373,374]. Speciﬁc
xposure to benzo (a) pyrene during development also resulted
n increased visceral adipose tissue weight in female offspring
375].The use of different model systems and exposures limits our
bility to determine the importance of PAHs as an important con-
ributor to obesity. There are limited human data on the association
f childhood obesity with maternal exposure to ambient PAHs,
owever a study by Rundle and colleagues [376] shows children
orn to mothers with the highest PAH exposures during pregnancy
ad higher body weights both at 5 and 7 years of age. The exten-
ive exposure of populations to air pollution necessitates a further
xamination of its overall effects and its speciﬁc contribution to
ncreased risk of obesity.
The most consistent human evidence that prenatal MDC
xposure is associated with obesity in offspring is for severalPlease cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
rganochlorine compounds: the in vivo metabolites of DDT (DDE),
s well as hexachlorobenzene (HCB) [309,310,377,378]. Persistent
rganic pollutants (POPs) are a class of chemicals that bioaccumu-
ate in tissues and magnify in the food chain [379]. They include PRESS
icology xxx (2016) xxx–xxx
some pesticides (DDT, HCB) and some industrial chemicals such as
polychlorinated biphenols (PCBs). While the use of these chemi-
cals is banned in many countries (PCBs, HCB and DDT) exposures
exist due to their persistence in the environment. In some coun-
tries like South Africa DDT is still used thus current exposure also
exists. Exposure during early gestation to some POPs, namely PCBs,
HCB and DDT, can lead to the development of obesity later in
life [380,310,378,381–385]. In rodent studies, prenatal exposure
to DDT followed by a high fat diet for 12 weeks in adulthood led to
the development of glucose intolerance, hyperinsulinemia, dyslipi-
demia and altered bile acid metabolism as well as reduced energy
expenditure and impaired thermogenesis as measured by reduc-
tions in core temperature in female offspring [386]. Six separate
epidemiology studies showed that prenatal DDE exposures were
associated with increased BMI  in the offspring at ages 1 and 3 [387],
at age 4 [378] and between ages 5–7 [381], as well as increased
overweight at age 6.5 [383], 7 years [377], and age 9 [388]. Prenatal
exposure to HCB has been associated with rapid growth in the ﬁrst
6 months of life and obesity in infancy and childhood [380,389].
Similarly, prenatal exposure to speciﬁc PCB congeners resulted in
increased BMI  at 14 months [384], at 1 and 3 yrs. of age [387], and
age 5 and 7 [390].
Effects of several POPs on growth may  be sex-speciﬁc. For exam-
ple, some associations between PCBs and measures of general or
central obesity are speciﬁc to girls [381,383,391] while the weight
gain due to DDT/DDE occurred in boys or girls depending on the
cohort and conditions of the study. In addition, it remains uncer-
tain to what extent the effects of these chemicals on long-term
growth may  be due to indirect effects, dependent on the mismatch
between a prenatal environment that can program offspring to sur-
vive in an environment that inhibits growth and the energy-dense
diets available in the postnatal environment. Many POPs for which
prenatal exposure is associated with obesity are also associated
with smaller size at birth [382], and thus associations with obesity
may  be, at least in part, related to rapid postnatal growth in these
children, similar to that observed in offspring of smokers and mal-
nourished infants [314,384,385,392]. In contrast to the human data,
there is a paucity of animal data on the role of POPs on obesity; this
area requires future study.
Data are limited, and sometimes inconsistent, for associations
between obesity and a number of chemicals in humans [310] and
animals [206]. For example, prenatal exposure to perﬂuorinated
compounds, chemicals used to repel grease stains in carpets and
clothing, was  not associated with subsequent adiposity in child-
hood [393] in a recent study, though a prior study found such
an association at age 20y [394]. Similarly, in animal models, one
study found in utero exposure to perﬂuorooctanoic acid (PFOA) led
to weight gain in offspring in outbred CD-1 mice [395] whereas
another inbred transgenic mouse model did not show any weight
gain [396]. The animal [397] and epidemiological data on obeso-
genic effects of prenatal exposure to arsenic [398,399] while limited
are consistent across species. Cd, Pb and As exposures are associ-
ated with smaller size at birth [400–403] which is a risk factor for
subsequent weight gain and greater adiposity. Prenatal exposure to
toxic metals is also related to higher leptin at birth [404,405]. Sim-
ilarly, limited but consistent data suggest obesity-related effects of
exposures to various ﬂame retardants in utero in humans with some
indication of sex-speciﬁc effects [406]. Developmental exposure of
rats to Firemaster 550, a ﬂame retardant mixture, was  associated
with weight gain later in life [407].
Taken together, these observations support the relevance of the
MDC hypothesis with respect to weight gain in animal and humanpting chemicals and metabolic disorders, Reprod Toxicol (2016),
studies.
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.2. MDCs and fat cell differentiation and development
Preadipocytes such as 3T3-L1 cells are often used as models
o test the ability of chemicals to induce adipogenesis. A recent
tudy used 3T3-L1 cells and MSCs to evaluate the effects of a collec-
ion of chemicals on adipogenesis and adipogenic gene expression
408]. This study found that several pesticides with different
hemical structures and modes of action, zoxamide, spirodiclofen,
uinoxyfen, ﬂudioxonil, tebupirimfos, forchlorfenuron, ﬂusila-
ole, acetamaprid, and pymetrozine all induced adipogenesis and
dipogenic gene expression in 3T3-L1 preadipocytes, whereas
uinoxyfen and ﬂudioxonil were also able to induce adipogenesis
nd adipogenic gene expression in MSCs [408,409] (Fig. 2). Diox-
ns and PCBs acting via the AhR alter the expression of important
enes related to adipogenesis, lipid metabolism and inﬂammatory
actors [410–414]. Activation of PPAR via exogenous ligands such
s rosiglitazone or TBT strongly promotes adipocyte differentiation
nd maintenance, together with the expression of genes involved
n lipid droplet formation, glucose uptake, fatty acid synthesis,
nd adipokine secretion [415,416]. Other studies have identiﬁed
PA [132,417,418], bisphenol A diglycidyl ether [419], aklylphe-
ols [420], phthalates [353,354,369,421,422] and ﬂame retardants
369,421,423,424] as well as organochlorine [425,426] and neoni-
otinoid pesticides [427] as chemicals that can promote adipocyte
ifferentiation.
In addition to differentiation of cell lines to adipocytes, it is also
ossible to regulate the fate of MSC  to result in increased num-
ers of fat cells. Because multiple signaling pathways converge to
egulate MSC  fate, there are numerous opportunities for extrinsic
actors to disrupt or modify differentiation. For example, the pes-
icides chlorpyrifos and carbofuran inhibited the ability of MSCs to
ifferentiate into bone [428] although the potential to differenti-
te into fat was not tested. Treatment with the organotin TBT or
he pharmaceutical rosiglitazone (ROSI) led to adipogenic differen-
iation of 3T3-L1 preadipocytes and MSCs in vitro [429,430] in a
PAR-dependent manner [431]. The fungicides triﬂumizole [354]
nd tolyﬂuanid [431] also promoted adipocyte differentiation and
ene expression in MSCs and 3T3-L1 cells. Prenatal exposure of
regnant mice to TBT or ROSI led to increased fat deposition at birth
364]. These exposures also diverted MSCs toward the adipogenic
ineage at the expense of the osteogenic lineage [429]. Although
dipogenesis and obesity have been the most studied outcome of
xposure to obesogens and MDCs, it should be obvious that the
ipotential switch between the adiopogenic and osteogenic lin-
ages opens an entirely new ﬁeld for the effects of MDCs on bone
evelopment and osteoporosis.
It is clear that chemicals can alter MSC  lineage allocation in
nimal models; however, there are no studies that examine MSC
ineage commitment in obese verses lean individuals. Nonetheless,
t is worth focusing on the potential consequences of chemi-
als altering MSC  lineage in humans. Obese individuals deﬁnitely
ave more fat cells than individuals of normal weight [106]. It is
ikely that obese individuals either were born with more fat cells
ecause of prenatal programming or developed them early in life
y mechanisms outlined above. It is probable that adipogenic stim-
li (such as exposure to chemical obesogens or inappropriate diet)
eceived perinatally or during adolescence permanently increased
at cell number. In turn, this creates an altered metabolic set-point
hat favors the storage of calories as fat. Once fat cell number is
rogrammed, the number cannot be altered readily by diet, exer-
ise, or even surgery [106]; many studies have documented the
xpansion of visceral fat depots in adults via increased adipocytePlease cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
umber [107,432,433] whereas permanent decreases in cell num-
er accompanied by weight loss have not been documented. It is
ossible to successfully shrink the size of existing fat cells by faith-
ul adherence to a restrictive diet and a vigorous exercise regimen. PRESS
icology xxx (2016) xxx–xxx 13
However, clinical studies repeatedly show that 83–87% of people
who achieve signiﬁcant weight loss regain the weight within a few
years [434,435]. These data strongly suggest that obese individuals
have altered metabolic set-points that favor calorie storage over
the long term.
There is no evidence that lipid-depleted fat cells automatically
undergo apoptosis. Indeed, it is difﬁcult to envision how such a
scenario would be favored over evolutionary time since healthy
fat cells would be required for the organism to survive periods
of fasting that regularly occur in hunter-gatherer societies. More-
over, expression of the satiety hormone, leptin closely parallels fat
mass and small fat cells secrete the least leptin making it likely that
shrunken fat cells would “crave to be ﬁlled” [436].
5.3. MDCs and neuroendocrine control of feeding and metabolism
Only a few studies have investigated the action of potential
MDCs on neural circuits/cells and on the resulting feeding behavior
and energy balance output. However, the neuroendocrine control
of these features could be an important target of environmental
chemicals.
Prenatal exposure to low doses of BPA alters the development
of the POMC system in a sexually differentiated way [437]. The
differences are evident when adult are exposed to a high-fat diet;
in particular, males show reduced POMC ﬁber innervation of the
PVN and increased NPY and AGRP expression in the ARC. Females
exposed to BPA show reduced POMC expression and ER expres-
sion patterns in the ARC similar to those seen in males, suggesting
a masculinizing effect of BPA. Also, fetal exposure to BPA in mice
alters food intake during puberty and in adulthood as well as leptin
and insulin levels, which in turn regulate the NPY system [319].
Organotin compounds such as TBT have not only peripheral
effects, but also may activate elements in the brain, in particular
in a crucial region for the regulation of food intake, the ARC [438].
Adult mice exposed to TBT for 4 weeks show profound alterations
of the leptin-NPY-NPY-Y1 receptor system [96,188]. Prenatal expo-
sure to TBT also induces hypothyroidism in the progeny, while the
acute treatment of pregnant females induces a dose-dependent
increase of T3-independent TRH transcription levels [439] in the
hypothalamus.
In summary, there are a number of important endpoints to study
the effects of MDCs on the regulation of food intake and metabolism
in the central nervous system. These include expression of the lep-
tin receptor, ER,  thyroid hormone receptor (associated also with
PPARy), the POMC-CART system, the NPY-AGRP system and their
receptor systems, and the dopaminergic system.
5.4. Sexually dimorphic effects
Because by deﬁnition they interfere with hormonal actions,
sex speciﬁc effects are expected for many MDCs. A critical aspect
regarding research on sex differences related to metabolic disease is
that until recently, the majority of biomedical studies have focused
only on males. With regard to the impact of MDCs on adipocity and
metabolism, it is well known that females differ dramatically from
males in subcutaneous fat deposition as well as in the endocrine
function of adipocytes. For example, females have higher circu-
lating concentrations of both leptin and adiponectin relative to
males [176] Thus, while not all studies that examined a few out-
comes of exposure in males and females report sex differences, one
would expect on detailed examination to ﬁnd sex differences. In
this regard, some studies have demonstrated that MDCs can mas-pting chemicals and metabolic disorders, Reprod Toxicol (2016),
culinize or feminize energy balancing traits depending upon type
and dose of the tested chemical, the timing of exposure and the
metabolic challenge. In experimental animals, sex-dependent dif-
ferences in body weight in response to prenatal or early postnatal
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xposure to low doses of BPA or DES have been reported; both
hemicals increased body weight in female rodents but decreased
r did not affect it in males [326,440]. A recent study has exam-
ned in detail the energy balance traits of mice prenatally exposed
ither to a low or a high dose of BPA or to DES showing that exposure
o BPA but not to DES hypermasculinized male and masculinized
emale mice (see also [437]). In addition, exposure to MDCs can
iminish, eliminate, reverse or widen sex differences in behav-
or, thus interfering with normal sexual differentiation of the brain
441–444] which can also affect metabolic processes. For example,
umerous studies have conﬁrmed the ability of BPA to affect the
odent developing brain in a sex-speciﬁc manner (for review see
445] even at very low doses [446,447], indicating that the brain
s a very sensitive target organ for BPA action. The cerebral cor-
ex, hippocampus and hypothalamus are key sexually dimorphic
egions in the rodent brain, and these brain areas can be affected by
re- and perinatal MDC  exposure, with sex speciﬁc effects observ-
ble even before the increase in gonadal hormones during puberty.
he developing hypothalamus has sex-speciﬁc vulnerability to BPA,
ith the preoptic area (POA) and mediobasal hypothalamus (MBH)
eing the most studied and robustly affected [448,449].
.5. Type 2 diabetes (T2D)
Evidence that chemicals can disrupt the function of the
ndocrine pancreas dates to the early 1940s when alloxan, a
lucose analogue which selectively destroys insulin producing
ells in the pancreas, was shown to promote type 1 diabetes in
abbits [450]. This was followed by the discovery that streptozo-
ocin similarly induced a diabetic state through selective -cell
estruction. Although humans are not exposed to alloxan or srepto-
otocin, they are used in animal research on diabetes. Initial human
vidence that synthetic chemicals promote the development of dia-
etes came from patients accidentally or intentionally exposed to
yrinuron (Vacor) [451]. Exposure to this rodenticide resulted in
-cell destruction and the development of type 1 diabetes [452].
ore recently, a patient exposed to high levels of the fungicide
hlorothalonil was reported to develop diabetic ketoacidosis, a con-
ition arising from insulin deﬁciency [453]. These and other studies
f environmental contaminants provide mechanistic insights into
he pathways by which MDCs may  promote diabetes pathogenesis
hrough defects in -cell physiology.
.5.1. MDCs and beta cell survival and function
.5.1.1. Cellular studies. A structurally diverse array of synthetic
nd inorganic toxicants disrupts -cell survival and function in cell
ines and isolated rodent islets. 2,3,7,8-tetrachlorodibenzodioxin
TCDD) reduces glucose-stimulated insulin secretion (GSIS) in iso-
ated islets [412,454,455]. Similarly, DDT impairs both GSIS as well
s insulin secretion in response to tolbutamide (a pharmacological
nsulin secretagogue) [456]. Among organotin compounds, triph-
nyltin was shown to disrupt cellular signaling in -cells and impair
nsulin secretion in response to a variety of stimuli [457]. Similarly,
norganic contaminants including both inorganic and methylated
rsenic [458–460], cadmium [461–463], and mercury [464] disrupt
-cell function (Fig. 2).
Interestingly, several compounds disrupt -cell signaling and
unction in a manner that promotes insulin release. In the RINm5F
ell line, a PCB mixture (Aroclor 1254) increased insulin secretion
nto the culture media, an effect recapitulated by coplanar PCB con-
eners [465]; TCDD also promotes continuous insulin release [466].Please cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
nterestingly, the insulin secretory effect resulted in a depletion of
ellular insulin content by PCBs [465] and TCDD was  proposed to
romote -cell “exhaustion” [466]. This suggests that prolonged
xposure to these compounds could result in insulin deﬁciency. PRESS
icology xxx (2016) xxx–xxx
BPA has been shown to augment GSIS; unlike TCDD and PCBs,
low doses of BPA augmented -cell insulin content in an ER
dependent manner [467]. A rapid action on insulin release was
shown to be dependent on ER expression, and was  conﬁrmed in
human as well as mouse islets [468,469]. Importantly, these effects
of BPA may  be representative of effects of other phenolic com-
pounds because nonylphenol and octylphenol were also shown to
augment GSIS in isolated rat islets [470].
In contrast to the extensive work examining MDC  effects on -
cell physiology, less is known about the effects of environmental
pollutants on -cell biology. In early studies, cobalt was  shown to
be toxic to -cells [471]. More recently, BPA has been shown to alter
calcium signaling in -cells [472]. Collectively, these data support
the theory that the endocrine pancreas is an important target for
the deleterious effects of MDCs on energy homeostasis.
5.5.1.2. Animal studies: exposures during adulthood. The strength of
evidence supporting environmental toxicants altering -cell phys-
iology is reinforced by animal studies that examine the effects of
whole-body exposure to a variety of MDCs on insulin secretion
and glucose homeostasis. Although the focus of this review is on
developmental exposure, in the case of MDCs exposures and T2D,
it is important to also mention adult studies. These studies demon-
strate a direct induction of insulin resistance without the need for
an increase in weight or adiposity.
Adult mice exposed to TCDD exhibited reduced glucose-
stimulated insulin release without concomitant hyperglycemia, an
effect that was absent in AhR-null mice [454]. Furthermore, TCDD-
exposed rats had islets depleted of insulin [412], similar to the
depletion of secretory granules observed with chronic exposure
to PCBs [473]. This contrasts with the effects of in vivo BPA expo-
sure, which augments insulin release and increases -cell insulin
content in a murine model [467]. Oral administration of TBT was
shown to promote hyperglycemia with reduced circulating insulin
levels accompanied by increased islet apoptosis and reduced cellu-
lar proliferation, suggesting a -cell defect as a contributing lesion
to TBT-induced metabolic dysfunction [474].
The use of genetic models of type 1 and T2D have also unlocked
the deleterious effects of MDCs on -cell biology. In the db/db
mouse model of T2D in which a defect in the leptin receptor
promotes the development of obesity and diabetes, exposure to
arsenic through drinking water enhanced the development of
hyperglycemia with concomitant reductions in insulin levels, sug-
gesting an arsenic-induced impairment in -cell function [475].
The non-obese diabetic (NOD) mouse, in contrast, is a model of
type 1 diabetes as these mice develop autoimmune inﬂammation of
the pancreatic islets (insulitis) and insulinopenic diabetes. Chronic
exposure to BPA modulates insulitis in female NOD mice with com-
plex concentration-dependent effects [476].
5.5.1.3. Epidemiological studies in adult human populations. The
effects of MDCs on -cell physiology in adult human studies are lim-
ited. In a Northern Mexican cohort, inorganic arsenic exposure was
associated with a reduction in -cell function, with the effect ampli-
ﬁed among those with T2D [477]. Along with larger epidemiologic
literature linking arsenic exposure to diabetes [478–480], other
studies have also found arsenic to be associated speciﬁcally with
measures of -cell dysfunction or reduced insulin secretion, more
strongly than with measures of insulin resistance [481,482]. Epi-
demiological studies also suggest that BPA, phthalates, dioxins, and
POPs including DDT metabolites and PCBs are associated with mea-
sures of altered glucose homeostasis including T2D [342,483–487].pting chemicals and metabolic disorders, Reprod Toxicol (2016),
In one recent study, urinary BPA concentration in US adults was
associated with an increase in -cell function, hyperinsulinemia
and insulin resistance [488] preferentially in males. These results
are similar to those obtained from studies performed in mice [467].
 ING ModelR
ive Tox
i
a
o
g
a
f
w
[
e
a
m
t
o
d
a
[
M
t
d
5
d
a
e
i
p
e
[
r
a
r
D
l
e
a
f
t
o
f
n
m
o
o
e
e
s
d
c
h
m
5
5
M
s
p
m
b
s
[
[
i
[ARTICLETX-7405; No. of Pages 31
J.J. Heindel et al. / Reproduct
Consistent with animal studies [489], a number of human stud-
es —including studies among children and numerous studies in
dults— suggest that DEHP is more strongly associated than are
ther phthalates with diabetes and other markers of impaired
lucose metabolism [362,490–493], perhaps because of greater
ctivation of PPARs. However, several other studies [494–496]
ound stronger evidence of associations with butyl phthalates,
hich have a weaker PPAR afﬁnity than do DEHP metabolites
497]. Because data thus far are limited, it is uncertain to what
xtent the mixed results in humans may  be due to factors such
s differences in exposures [494], measurement errors in esti-
ates of exposure [347], or sex-speciﬁc effects [498]. Moreover,
o date very few epidemiological studies have examined the devel-
pmental or perinatal exposures thought to have the most potent
iabetogenic effects [499], though recent animal studies support
dverse effects of ongoing exposures including those in adulthood
500,501]. Nonetheless, overall, these studies support the idea that
DC-induced disruptions in -cell function may  mediate some of
he observed associations between environmental chemicals and
iabetes in human populations.
.5.1.4. Animal studies: gestational and perinatal exposures. While
isruptions in glucose homeostasis due to diminished insulin
ction result from developmental exposure to several chemicals,
vidence speciﬁcally linking MDCs to impaired -cell function
s less common (Fig. 3). In a rat model, females exposed to the
hthalate DEHP throughout gestation and perinatal development
xhibited hyperglycemia in the presence of reduced insulin levels
502]. Histological evaluation of pancreatic islets from weanlings
evealed reductions in -cell mass, reduced islet insulin content,
nd disruptions in -cell ultrastructure [489]. In a similar model,
estriction of exposure to days 9–21 of gestation, albeit to higher
EHP levels, similarly altered -cell function and reduced insulin
evels with hyperglycemia [503].
In the NOD model of type 1 diabetes, in utero and perinatal
xposure to BPA increased the severity of insulitis at 11 weeks of
ge and increased the prevalence of diabetes at 20 weeks of age in
emale mice [504]. Interestingly, a recent study also demonstrated
hat BPA exposure during pregnancy promotes the development
f glucose intolerance in later life through impairments in -cell
unction and mass [505]. This suggests that exposures during preg-
ancy may  alter the long-term metabolic trajectory of both the
other and her offspring. These studies support extending the view
f ‘developmental windows’ beyond early life, as important periods
f sensitivity to disruptions in -cell function may  be mediated by
xposure to environmental toxicants during other critical periods,
.g. pregnancy.
Collectively, experimental evidence from cell lines to humans
upports the endocrine pancreas as a target for disruption by
iverse MDCs. Further work is required to determine the exposure
onditions under which - and -cell physiology is disrupted in
umans to better characterize the threat of exposures to MDCs to
etabolic health.
.5.2. MDCs, insulin action and glucose disposal
.5.2.1. Cellular models. In addition to data demonstrating that
DCs disrupt insulin production, an increasing body of evidence
uggests that a variety of MDCs have the capacity to impair
eripheral insulin action. In diverse cell line and organ culture
odels of insulin-responsive tissues, an array of compounds have
een shown to impair insulin signal transduction or insulin-
timulated glucose disposal, including TCDD [506,507], tolylﬂuanidPlease cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
508], inorganic and methylated arsenic species [509,510], DEHP
511,512], and POPs [413]. In one model, BPA was  also shown to
nhibit insulin-stimulated glucose utilization in 3T3-L1 adipocytes
414] and another study showed that BPA can increase basal and PRESS
icology xxx (2016) xxx–xxx 15
insulin-stimulated glucose uptake in 3T3-F442A cells [409]. BPA
also stimulated secretion of pro-inﬂammatory cytokines IL-6 and
TNF while inhibiting the anti-inﬂammatory cytokine adiponectin
from human adipoctyes in culture [513]. Collectively, these data
suggest impairments in insulin action may  result from exposure
to a variety of environmental MDCs; however, dose, duration, and
model system may  alter the phenotypic response of some tissues
to these compounds.
5.5.2.2. Adult animal studies. Evidence that MDCs disrupt cellu-
lar energy handling is supported by data from animal models in
which multiple compounds have been shown to promote insulin
resistance. For example, in vivo exposure to DEHP down-regulates
expression of adipocyte insulin signaling intermediates [514],
while rats exposed to BPA demonstrated a reduction of insulin sig-
naling intermediates in both muscle [515] and liver [516]. Cadmium
exposure has been shown to promote glucose intolerance with a
speciﬁc reduction in adipose expression of Glut4 [517] and TCDD
has been shown to also reduce glucose uptake in adipose and brain
[518,519]. In addition, the fungicide tolylﬂuanid promotes glucose
intolerance with concomitant global and adipose-speciﬁc insulin
resistance, with the latter resulting from a speciﬁc down-regulation
of insulin receptor substrate-1 (IRS-1) [520].
While less speciﬁc, a variety of studies have also shown that
exposure to various organic and inorganic toxicants promotes
global insulin resistance or glucose intolerance with associated
shifts in serum insulin levels. For example, in vivo exposure to inor-
ganic arsenic promotes glucose intolerance with concordant insulin
resistance [475,521], including accentuation of the inherent insulin
resistance of pregnancy [522]. Extended exposure to air pollution
particular matter (PM2.5) for 24 weeks induced whole body insulin
resistance in mice [523]. Acute and chronic malathion exposure
resulted in increases in both glucose and insulin levels in rats [524].
Chronic exposure to POPs has also been shown to promote insulin
resistance [500]. Similarly, BPA promotes insulin resistance in mice
[467], and this effect can be observed with exposures as short as
8 days [525]. In addition to effects on -cells, in vivo studies of TBT
exposure in mice demonstrate hyperinsulinism [526].
While these studies emphasize the diverse array of compounds
that can alter insulin action, key factors may  modulate the ulti-
mate metabolic phenotype. For example, female mice exposed to
arsenic develop glucose intolerance; however, the etiology may
be inﬂuenced by the background hormonal status of the animal
as ovariectomized mice exhibit elevated insulin levels while those
with intact ovaries have reduced insulin levels [527]. Furthermore,
an animal’s genetic background may  also inﬂuence the phenotype.
In one study, inorganic arsenic was  shown to preferentially induce
glucose intolerance in diabetic db/db mice but not non-diabetic
mice [475]. Importantly, additional metabolic stressors such as high
fat feeding may  also modify MDC  effects on energy homeostasis.
Atrazine has been shown to promote insulin resistance, an effect
exacerbated by a high fat diet [528]. BPA also promotes glucose
intolerance and impair insulin action in a chronic model of expo-
sure coupled with a high fat diet [529]. Interestingly, PCB77 and
PCB126 were shown to impair glucose tolerance with the induc-
tion of systemic insulin resistance when coupled with a low fat
diet; however, the effect of PCB77 on glucose tolerance was  absent
in the context of high fat diet but reemerged with weight loss [530].
Indeed, the evidence for diet-PCB interactions in promoting insulin
resistance may  be quite complex and congener-speciﬁc as expo-
sure to the PCB mixture Aroclor 1254 induced insulin resistance in
both lean and diet-induced obese states [531]. Similarly, in one epi-pting chemicals and metabolic disorders, Reprod Toxicol (2016),
demiology study, effects of PCBs on odds of diabetes appeared to be
modiﬁed by intakes of fruits and vegetables [532]. Conversely, rats
exposed to PM2.5 developed increased insulin levels and elevated
HOMA-IR only in the context of a high fat diet [533] and Aroclor
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260 administered to mice fed a high fat diet altered carbohydrate
etabolism at multiple levels including glucose tolerance, insulin
esistance/sensitivity, adipokines, pancreatic insulin secretion, and
epatic gluconeogenesis [534]. Taken together, this evidence sug-
ests that the relationships between MDCs and dietary metabolic
tressors are complex, with an ultimate phenotype that may  be
xposure-speciﬁc.
.5.2.3. Animal studies: gestational and perinatal exposures. Vari-
us models have suggested that imbalances in insulin action can
rise from MDC  exposures during development. BPA enhanced the
nsulin resistance of pregnancy, with female offspring demonstrat-
ng higher insulin levels and males exhibiting glucose intolerance
ith systemic insulin resistance [535]. Insulin resistance was  also
bserved in BPA-exposed rats [536], while another mouse model
imilarly demonstrated glucose intolerance with insulin resistance;
owever, the effect was observed only at low doses[319]. Metabolic
tressors like high fat diet may  be additive to the BPA-induced
nsulin resistance [329]. Indeed, high-fat diet potentiated GSIS
mpairments elicited by low doses of BPA given subcutaneously
537]. In the CD-1 mouse, however, developmental exposure to
PA did not alter glucose homeostasis in adult mice fed a normal
how or high fat diet [331]. Overall, these ﬁndings suggest that
evelopmental BPA exposure can alter metabolism, albeit the ulti-
ate metabolic phenotype may  be modulated by genotype, diet
nd exposure patterns.
Additional studies have suggested that developmental exposure
o other compounds can promote alterations in insulin action. For
xample, exposure to low doses of PFOA in midlife were shown to
ncrease insulin levels [395], while PFOS exposure during gestation
nd early postnatal development resulted in glucose intolerance
nd insulin resistance [538]. Rats exposed to PFOS from gestation
ay 0 to postnatal day 21 also shown exhibited glucose intolerance
ith elevated insulin levels [539].
Developmental exposure to DEHP induces a complicated pheno-
ype with the development of hyperglycemia with reduced insulin
evels in female rats, while male offspring had elevated insulin lev-
ls but normal glucose tolerance [489]. In another model, DEHP
xposure led to glucose intolerance with insulin resistance in the
ffspring, although this model also revealed central defects in -
ell function as well [503]. Sex-speciﬁc effects of DEHP on measures
f insulin resistance have been reported in some epidemiological
tudies [493], but not others [540].
These data suggest that both adult and developmental expo-
ures to various MDCs have the capacity to modulate insulin action
lobally as well as at the cellular level. This conclusion is further
upported by a number of studies, not discussed, in which MDC
xposure promoted glucose intolerance without examination of
nsulin levels or action. However, the precise mechanism(s) by
hich this common phenotype occurs remains somewhat obscure.
xamining the totality of the data, several molecular pathways
re implicated as potential mechanisms of altered insulin action.
hese include increased production of proinﬂammatory cytokines
hat induce insulin resistance such as TNF and IL-6 [506,523,541],
ncreased oxidative stress [464,475,514,524,542], and mitochon-
rial dysfunction [528], which may  also increase oxidative damage.
urther work is required to fully characterize the modes by which
DCs promote impaired insulin action to devise strategies to mit-
gate their adverse effects on global energy homeostasis.
.5.3. MDCs and energy homeostasis
In addition to the effects of MDCs on insulin production andPlease cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
ction, speciﬁc defects in intermediary metabolism have also been
escribed for MDCs using a variety of model systems. For example,
n the 3T3-F442a cell line, TCDD reduces expression of lipopro-
ein lipase [507], suggesting one mechanism by which MDCs may PRESS
icology xxx (2016) xxx–xxx
promote hypertriglyceridemia. PBDE exposure inhibits adipose
glucose oxidation while augmenting isoproterenol-induced lipol-
ysis [543], potentially increasing circulating free fatty acid levels,
which are substrates for hepatic triglyceride synthesis.
Additional lipid abnormalities may  be induced by perinatal
exposure to 4-nonylphenol which has been shown to increase
serum total cholesterol [420]. Disruptions in hepatic metabolic
function were shown with subchronic exposure to malathion,
which induced hyperglycemia with evidence of increased hepatic
gluconeogenesis and glycogenolysis [544]. Chronic intake of DEHP
impairs glucose tolerance with an alteration in glycolytic interme-
diates in both liver and muscle that were suggestive of impaired
lactate as well as glucose handling [545]. In utero and lactational
exposure to BPA in a rat model demonstrated a reduction in hepatic
glycogen content at 21 weeks of age with evidence that the pro-
moter for hepatic glucokinase was hypermethylated, suggesting a
reduction in the expression of this key enzyme [536]. In a multigen-
erational rat model, BPA exposure in the F0 generation promoted
glucose intolerance and insulin resistance in the F2 generation
with an associated reduction in hepatic glucokinase expression and
concomitant hypermethylation of the gene promoter [546]. Inter-
estingly, adult mice exposed to BPA have also been shown to exhibit
reduced hepatic glucokinase activity [547]. This suggests that dis-
ruptions in hepatic glucose handling may  be a common mode by
which MDCs promote metabolic dysfunction.
5.6. MDCs, hepatic steatosis, and hyperlipidemia
Developmental studies examining MDCs and liver health
endpoints have been conducted in laboratory animals, but epi-
demiology studies examining the developmental basis of these
diseases are lacking. This is likely due to the relatively long time to
develop clinically apparent human liver disease owing to the slowly
progressive nature of hepatic ﬁbrosis. Compounding the problem,
routine clinical biomarkers (e.g. alanine aminotransferase) may be
insensitive for the detection of environmental liver disease[548]
Novel biomarkers for fatty liver disease and ﬁbrosis [549] are being
developed for clinical use, and perhaps these could be applied to
future environmental epidemiology studies. Due to the relative
lack of epidemiological data on developmental MDC  exposures in
steatosis and hyperlipidemia, post-developmental studies (adoles-
cent and adult) provide ‘proof of concept’ and thus are reviewed
below.
5.6.1. Adult MDC  exposures, steatosis and hyperlipidemia
Hepatic steatosis is likely to be the most common patho-
logic liver responses to chemical exposures [163]. Indeed, hepatic
steatosis was noted in approximately 8–10% of rodent stud-
ies warehoused in the Environmental Protection Agency’s (EPA)
Integrated Risk Information System (IRIS) database and the Tox-
icological Reference Database (pesticide) [162,550]. Furthermore,
in the Chemical Effects in Biological Systems (CEBS) data repository
of the US National Toxicology Program (NTP), 329 rodent studies
of 81 unique chemicals reported hepatic steatosis [550]. Whatever
its etiology, hepatic steatosis is invariably associated with insulin
resistance [163]. However, this interaction is complex as fatty liver
disease is both a cause and effect of insulin resistance.
While some chemicals (e.g. vinyl chloride) appear to directly
cause steatosis and steatohepatitis [551], other chemicals such as
non-dioxin like PCBs merely modify the hepatic response to diet-
induced obesity [534]. These chemicals may  be a ‘second hit’ in
the progression of diet-induced steatosis to frank steatohepatitis,pting chemicals and metabolic disorders, Reprod Toxicol (2016),
which may  further progress to cirrhosis and hepatocellular carci-
noma. Many non-dioxin like PCBs interact with NR1 class nuclear
receptors such as PXR and CAR [552]. However, the role of MDC-
nuclear receptor interactions in fatty liver disease is likely to be
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omplex, as PPAR agonists (e.g. obesogens) have been proposed
s treatments for non-alcoholic fatty liver disease and associated
nsulin resistance [553]. Nuclear receptor crosstalk especially at
he liver X receptor response element is also likely to be important,
ut is currently understudied. Other proposed mechanisms include
xidative/carbonyl stress, endoplasmic reticulum stress, mitochon-
rial dysfunction, increased cytokine production, increased hepatic
ipid synthesis/uptake and impaired VLDL synthesis and secretion
162,163]. Many of the environmental chemicals associated with
teatosis are organochlorines. Of the compounds in the US Envi-
onmental Protection Agency’s Integrated Risk Information System
IRIS) that induced steatosis in rodents following oral (dietary)
reatment, the most potent (mirex, chlordecone, chlordane) were
tructurally similar, highly chlorinated molecules ( > 8 chlorines)
162]. While these data suggest that highly halogenated environ-
ental chemicals could be of particular interest in steatosis, more
ata are required.
Key chemical classes identiﬁed in adult steatosis studies include
olvents and volatile organic chemicals; POPs and pesticides; and
etals [163,550]. Solvent exposures have historically been asso-
iated with steatosis and liver injury in the occupational health
iterature [551,554]. These data were recently reviewed by the
nstitute of Medicine and the National Research Council which
oncluded that there was “. . .evidence of an association between
hronic exposure to solvents in general and hepatic steatosis that
ould persist after cessation of exposure” [555,556]. Unfortunately,
t is difﬁcult to assess biomarkers of prior solvent exposures, and
pidemiological data on the impact of solvent exposures in human
ohorts are lacking.
Exposure to BPA is associated with liver enzyme abnormali-
ies reﬂective of liver injury in population-based studies [341,557],
lthough pathologic data were not provided. Regarding dyslipi-
emia, non-signiﬁcant trends were observed for BPA in pediatric
HANES populations [558]. However, prolonged (8-month) expo-
ure of male mice to low BPA doses induced hypercholesterolemia
ith upregulation of key genes involved in cholesterol biosynthe-
is including sterol regulatory element-binding protein 2. Whole
ody de novo cholesterol synthesis was also increased as seen
y the plasma lathosterol-to-cholesterol ratio [501]. Interestingly,
he food contaminant 1,3-dichloro-2-propanol induced hyperlipi-
emia with increased LDL/HDL ratio in mice via the AMP-activated
rotein kinase (AMPK) signaling pathway [559].
Exposures to POPs and pesticides have been associated with
atty liver disease in adults. In the NHANES study, PCB exposures
ere associated with ‘unexplained alanine aminotransferase (ALT)
levation’, a surrogate marker for fatty liver [560]. The observed
ssociation between PCB exposures and ALT was  subsequently
onﬁrmed in NHANES by two other independent groups using
ifferent statistical techniques; and also in the Prospective Inves-
igation of the Vasculature in Uppsala Seniors (PIVUS) cohort
561–563]. Likewise, associations between organochlorine pesti-
ides or their metabolites and liver enzymes have been seen for
LT [561] and gamma  glutamyl transferase [564]. Perﬂuorinated
hemical exposures were also positively associated with ALT in
HANES [565], and this association was more evident for PFOA
xposures in obese adults [566]. Positive associations were also
een between both PFOA and PFOS exposures in adult partici-
ants of the C8 study (n = 47,092 subjects) [567]. Animal studies of
CBs [160–162,534,550,568], organochlorine pesticides [162], and
FOA [569] suggest that the liver enzyme abnormalities reported
n these adult epidemiological studies could be due to fatty liver
isease.Please cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
In population-based studies of hyperlipidemia, PCB exposures
ere associated with longitudinal increases in LDL cholesterol
570]. However, other studies reported nonlinear associations
etween PCBs and organochlorine pesticides with hyperlipidemia PRESS
icology xxx (2016) xxx–xxx 17
[571,572]. PCB treatment has been associated with hyperlipidemia
in some [573], but not all rodent studies [548]. The chlorinated
insecticide, lindane, interacts with ER [574], and high-dose lin-
dane exposure (12 mg/kg × 20 days) in rats increased serum total
cholesterol and triglycerides while decreasing HDL cholesterol
[575]. On the other hand, TCDD decreased total cholesterol, LDL,
and HDL in a rodent study suggesting an AhR-mediated serum lipid
clearance and decreased hepatic efﬂux [576].
Metals/metalloids have also been associated with abnor-
mal  liver function and hyperlipidemia. In Bangladesh, drinking
from arsenic contaminated wells was associated with increased
ALT [577]. Chronic arsenic exposures were also associated with
increased triglycerides in a cross-sectional study [578]; in rats,
arsenic increased serum cholesterol, triglycerides, free fatty acids
and phospholipids in association with increased oxidative stress
and hepatic mitochondrial damage [579] as well as ALT when
combined with an obesogenic agent [580,581]. Lead and mer-
cury exposures were associated with the fatty liver surrogate
biomarker, ‘unexplained ALT elevation’ in adult NHANES [560]; and
lead, but not mercury, was associated with ALT, plasma triglyc-
erides and LDL, in Iranian adolescents [582]. In mice, however,
methylmercury markedly and speciﬁcally increased total and LDL
cholesterol [583]. Cadmium exposures were also associated with
ALT in adult Korean NHANES participants [584] and Iranian ado-
lescents [585].
Animal studies suggest that the observed ALT elevations in
the adult/adolescent populations following exposures to arsenic
[581], mercury [586], and cadmium [587] may be due to fatty liver
disease. Thus, data implicate post-developmental exposures to
speciﬁc volatile organic compounds/solvents, plasticizers, POPs,
and metals/metalloids in hepatic steatosis and dyslipidemia.
The herbicide, atrazine, is a chloroplast inhibitor which has
also been associated with mitochondrial dysfunction and NAFLD
in rodents [528,588,589] Respiratory routes of exposure have also
been associated with the development of fatty liver disease via the
lung-liver axis. For example, air pollution and particulate matter
were associated with steatohepatitis in rodents [590,591], though
mechanisms including toll-like receptor activation. However, con-
ﬁrmation in human studies is required. While smoking has not
historically been considered to be a clinically signiﬁcant factor in
the pathogenesis of liver disease, recent data demonstrate a link
between active and secondhand smoke in the development of both
adult and pediatric NAFLD [592–595].
5.6.2. Developmental MDC  exposures and hepatic steatosis
Given the liver’s importance in toxicology, it is somewhat sur-
prising that only scattered evidence exists to characterize pathways
and patterns of its altered functional development. Nevertheless,
a number of rodent studies suggest that speciﬁc developmental
perturbations to liver programming may  inﬂuence the long-term
predisposition to steatohepatitis and MetS. Of great interest is the
multi-generational effect of maternal high-fat feeding, which may
prime steatohepatitis in adult mice offspring [596–598] (Fig. 4).
These effects result from mechanisms similar to those observed
in adult steatohepatitis studies including increased lipogenic gene
expression with mitochondrial dysfunction and decreased beta oxi-
dation, due in part, to altered PPAR/PPAR expression; microRNA
changes; increased oxidative stress with reduction in hepatic
antioxidant enzymes; and increased inﬂammation.
Likewise, maternal exposures to chemicals have been associated
with altered hepatic metabolism and steatosis in offspring. Expo-
sure throughout gestation and perinatal development to BPA maypting chemicals and metabolic disorders, Reprod Toxicol (2016),
further exacerbate the nonalcoholic steatohepatitis-like phenotype
in male rats that were fed a high-fat diet post-weaning; in partic-
ular, BPA worsened the accumulation of lipids in hepatocytes as
well as liver inﬂammation and oxidative stress ﬁbrosis [599]. Liver
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unction markers were unimpaired in BPA-exposed rats kept on
 standard diet; however, these animals showed effects sugges-
ive of subtle alterations of liver programming, such as moderately
ncreased steatosis and altered expression of insulin signaling ele-
ents.
Epigenetic changes may  be a hotspot in altered liver program-
ing: developmental BPA exposure alters gene methylation in
ouse liver, in particular concerning genes relevant to metabolism
nd stimulus response. As observed for other molecular and cel-
ular effects of EDCs, the effects of BPA were different at low and
igh dose levels (0.05 and 50 mg/kg bw, respectively) [600]. Over-
ll, the ﬁndings suggest that the developmentally-induced altered
iver methylome increased insulin resistance phenotypes in adults.
ome of these effects may  have been related to hepatic changes
ncluding altered nuclear receptor expression (PPAR/PPAR)  key
egulators of energy metabolism, mitochondrial dysfunction, and
NA methylation.
Gestational exposures to, DEHP, also resulted in hepatic steato-
is in offspring as well as decreased glycogen storage in males,
ut with a delayed shift to glycogen-dependent metabolism of
he mature hepatocyte [601]. This phenotype could stem from
he DEHP-PPAR interactions inﬂuencing expression of lipid
etabolism genes such as microsomal triglyceride transfer protein
602]. However, DEHP also interacts with other nuclear receptors
ncluding CAR and PXR. While there is no direct evidence of the
nvolvement of CAR and/or PXR in the DEHP-induced effects on liver
etabolic programming, nevertheless, their involvement is plausi-
le and deserves attention for potential human disease relevance.
hile DEHP is a less potent human than rodent PPAR activator, it
ore potently activates human CAR [603].
While probably best characterized for plasticizers (BPA,Please cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
EHP), developmental exposures to other toxicants including
enzo[a]pyrene, TBT, PBDEs, and pesticides have also been asso-
iated with development of fatty liver disease and/or abnormal
epatic lipid metabolism in rodents [365,375,550,604]. Rats perina-d sites of action of metabolism disruptors.
tally exposed to polybrominated diphenyl ether 47 (PBDE-47) had
increased blood cholesterol levels [605]. Altered blood cholesterol
was likely a result of reduced hepatic Cyp7a1 expression, a critical
enzyme for the conversion of cholesterol into bile acids [604,605].
Exposure to BDE-47 and DE-71 (a commercial mix  of PBDE) resulted
in transcriptomic enrichment of genes of lipid metabolism in rat
livers [604,605], including long-term systematic activation of path-
ways of , , and -oxidation of fatty acids.
Overall, the available evidence indicates that liver programming
may  be an important target for MDCs that increase predisposi-
tion to MetS. Relevant morphological changes include increased
lipid accumulation and depleted glycogen storage in hepato-
cytes; changes at molecular or biochemical levels may  include
altered methylation patterns, altered nuclear receptor cross-talk,
mitochondrial dysfunction, and enhanced free radical production.
However, more data are needed to deﬁne the set of chemicals that
result in steatosis and dyslipidemia following developmental expo-
sure and the mode of action of these chemicals in fatty liver disease.
While the animal study data are compelling for developmental BPA
exposures and steatosis, signiﬁcant knowledge gaps exist for other
MDCs. Epidemiological data are also very limited in this area.
5.7. MDCs and metabolic syndrome
As noted above there are MDCs that can result in obesity, T2D
or lipid disorders. What is striking is that when multiple end-
points were examined within individual studies, in many cases an
MDC  caused disruptions in multiple disease pathways leading to
what could be called MetS. Table 1 shows that indeed many EDCs
should be characterized as MDCs as they can cause multiple dis-
ease/dysfunctions, even when not all of the metabolic endpointspting chemicals and metabolic disorders, Reprod Toxicol (2016),
were measured in the same experiment. We highlight examples
here to show that indeed there are MDCs that can affect multiple
tissues leading to multiple metabolic disorders and in some cases
to MetS due to their ability to induce weight gain, glucose intol-
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Table  1
Metabolism Disruptors and Metabolic Disruption.
Chemical Obesity T2D Lipid Disorders
Chemical Obesity T2D Fatty Liver
Bisphenol A *** *** ***
DEHP *** *** ***
DDT/DDE *** ** *
PBDE *
PFOA ** ***
PFOS * ***
TBT  *** *** ***
Air  Pollution ** *** ***
PAHs
PCBs * *** ***
TCDD ** ***
Cadmium * **
Atrazine * **
Arsenic ** *** ***
HCB *
Trifumizole *
Benzo(a) pyrene * **
Tolyfuanid * *
Smoking/nicotine *** ** ***
This table has been developed from the literature cited in this review. The number
of  *** indicates the strength of the evidence. * indicates one manuscript animal
or  human, ** indicates one manuscript in animal and human or more than one
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mission as a result of exposure to chemicals or altered nutritionanuscript in either animal or human and *** indicates more than one manuscript
n both animal and human studies, or multiple manuscripts in animal studies.
rance and lipid disorders. These data indicate it is important to
xamine more than one endpoint and tissue to deﬁne an action of
 suspected MDC.
The ﬁrst example comes from developmental exposure to BPA,
hich can induce glucose intolerance and insulin resistance [329],
nd impairments -cell function and mass [505]. Developmental
xposure to BPA has also been shown to cause weight gain in off-
pring in some animal models and human studies (reviewed in
337]). BPA exposure throughout gestation and perinatal develop-
ent exacerbates a nonalcoholic steatohepatitis-like phenotype in
ale rats that were fed a high-fat diet post-weaning; in particular,
PA worsened the accumulation of lipids in hepatocytes as well as
iver inﬂammation and oxidative stress ﬁbrosis [599].
Similarly, rats exposed to DEHP throughout gestation and
erinatal development exhibited hyperglycemia in the presence
f reduced insulin levels [502] along with reductions in -cell
ass, reduced islet insulin content, and disruptions in -cell
ltrastructure [489]. Sex-speciﬁc effects of DEHP on measures of
nsulin resistance have been reported in some epidemiological
tudies[493]. Gestational exposures to DEHP resulted in hepatic
teatosis in offspring as well as decreased glycogen storage in
ales, but with a delayed shift to glycogen-dependent metabolism
f the mature hepatocyte [601]. Prenatal exposure of mice to DEHP
esults in increased body weight as well as numbers and size of
dipocytes in male offspring in several studies from different labs
sing different models [353–356].
DDT and its metabolites have been associated with increased
isk of higher body weight, insulin resistance, T2D and dyslipidemia
n human studies [572,606]. In rodent studies, female offspring
xposed prenatally to DDT followed by a high fat diet for 12 weeks
n adulthood developed glucose intolerance, hyperinsulinemia,
yslipidemia and altered bile acid metabolism as well as reduced
nergy expenditure and impaired thermogenesis [386]. DDT effects
ere also transmitted across generations resulting in obesity in the
3 generation [607].
PBDEs have also been associated with development of fatty liverPlease cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
isease and/or abnormal hepatic lipid metabolism in rodent stud-
es [365,375,550,604]. Exposure to BDE-47 and DE-71 resulted in
ranscriptomic enrichment of genes of lipid metabolism in rat livers PRESS
icology xxx (2016) xxx–xxx 19
[604,605], including long-term systematic activation of pathways
of , , and -oxidation of fatty acids. Developmental exposure in
a rodent model to a speciﬁc PBDE mixture, Firemaster 550, resulted
in weight gain in the offspring [407].
Prenatal exposure to TBT in mice promotes adipocyte differenti-
ation that results in increased lipid accumulation and adipose tissue
while reducing muscle mass that persists into adulthood and across
generations [307,364]. It also increases adiposity in zebraﬁsh [370].
One epidemiology study noted that prenatal TBT exposures were
associated with a non-signiﬁcant trend towards higher weight gain
in the ﬁrst three months of life [371]. In a transgenerational study,
TBT resulted in hepatic steatosis through the F3 generation. Finally
TBT was  shown to promote hyperglycemia with reduced circulat-
ing insulin levels accompanied by increased islet apoptosis and
reduced cellular proliferation, suggesting a -cell defect as a con-
tributing lesion to TBT-induced metabolic dysfunction [474].
Among the other chemicals summarized in Table 1, develop-
mental exposure to PAHs in a rodent model induce obesity, insulin
resistance and inﬂammation in adults on a high fat diet [373,374]. In
a human cohort, children of mothers with the highest PAHs expo-
sure during pregnancy had increased weight at 5 and 7 years of
age [376]. Prenatal exposure to speciﬁc PCB congeners in birth
cohort studies was shown to result in increased BMI  in offspring
[384,387,390]. Arsenic also deserves mention because of its speciﬁc
association with insulin dysregulation and T2D and liver toxicity
[475,521,527,581]
5.8. MDCs and transgenerational metabolic disruption
A variety of stressors including high-fat, high-sugar diets, low
protein diets and environmental chemicals can induce transgen-
erational inheritance of metabolic diseases [608]. Several recent
papers have shown that the effects of MDC  exposure in pregnant F0
animals were propagated until at least the F3 generation (reviewed
in [307,609,610]). This is signiﬁcant because when exposures occur
in the maternal lineage, the F0 and F1 animals are directly exposed
to the chemical and the F2 generation is exposed as germ cells
within the gestating F1 animals. The F3 generation is the ﬁrst
generation that has not received any direct chemical exposure;
therefore, effects observed in F3 and beyond are considered to be
transgenerational and permanent, and are distinguished from the
multigenerational effects in F1 and F2 animals [611].
Exposure of pregnant F0 animals to low, environmentally-
relevant levels of TBT in their drinking water led to increased fat
depot size, MSCs reprogrammed toward the adipogenic lineage and
hepatic steatosis through the F3 generation [365]. Effects on fat
depot size were more pronounced in F1 females than F1 males.
Prenatal TBT exposure permanently alters MSC  cell fate in both
males and females and caused hepatic steatosis and altered hepatic
gene expression in both males and females through the F3 gen-
eration. Skinner and colleagues have similarly shown that plastic
components such as BPA, DEHP, dibutyl phthalate [355], a mixed
hydrocarbon mixture (jet fuel JP-8) [355], and DDT [355] all lead
to a transgenerational predisposition to obesity in the F3 genera-
tion. The molecular mechanisms remain unclear; however, many
of the toxicants work through nuclear receptors [610] that are
likely linked to epigenetic changes [612,613] that likely play a sig-
niﬁcant role in the transgenerational effects. Imprinting, altered
DNA methylation, histone modiﬁcations and copy number variants
have all been implicated in transgenerational phenotype trans-pting chemicals and metabolic disorders, Reprod Toxicol (2016),
[609,614–616]. Candidate sperm epimutations were also identiﬁed
that could be involved in the etiology of the transgenerational obe-
sity and other disease outcomes Guerrero-Bosagna, Weeks [617].
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. Conclusions: a perfect storm for metabolic disease
Many of the studies discussed above highlight the importance
f development as a sensitive time for programming all aspects
f metabolism. Environmental chemicals with endocrine activity
an alter programming of metabolism; this fact, along with the
mportance of diet during development and throughout life on
etabolism, and the role for exercise in controlling weight and glu-
ose metabolism, leads to the perfect storm for metabolic disease.
n utero, and the ﬁrst few years of life, are critical periods where the
ensitivity or set point for obesity, diabetes and liver disease are
stablished. We  have herein shown that sensitivity or set points
or the development of these diseases can be altered by MDCs that
nterfere with the normal developmental trajectories of adipose tis-
ue, pancreas, muscle, liver, GI tract and the brain. These set points
re also inﬂuenced by diet and nutrition in utero and early child-
ood years, thus nutrition and MDC  exposures during development
re the key along with genetic background for setting the stage for
ll metabolic diseases.
These metabolic diseases may  not manifest until later in life
hen the system is challenged by over-nutrition and/or lack of
xercise. MDCs can change the expression of genes involved in the
ontrol of adipogenesis as well as glucose and lipid metabolism.
xposure to MDCs, together with excess calories and lack of exer-
ise, would increase the susceptibility to these disease epidemics.
hus, we propose that some individuals are more prone to gain
eight due to both their genetic background and the effects of
evelopmental exposures to MDCs that are critical for setting the
ensitivity or susceptibility of the tissues for metabolic disruption
ater in life.
Some recent publications support increased susceptibility to
besity due to environmental exposures. Developmental expo-
ure to BPA induced weight gain due to increased food intake,
hanges in brain satiety neurons [618] and decreased activity and
nergy expenditure in females Johnson, Painter [619]. Similarly,
renatal nicotine leads to increased body weight due to a marked
ypertrophy of adipocytes and fat deposition along with decreased
pontaneous physical activity later in life, cold intolerance, and also
ncreased sensitivity to the effects of high fat diet [311]. In addition,
here are many examples of the effects of developmental expo-
ures to MDCs that are exacerbated by high fat diet later in life,
gain indicating that developmental exposures increase the sus-
eptibility to obesity (and other metabolic diseases) but may  need
 “second hit” later in life for the effects to actually become appar-
nt as disease. For example, developmental exposure to PAH results
n obesity, insulin resistance and inﬂammation only after a high fat
iet as adults [373,374]; the effect of atrazine on insulin resistance
as exacerbated by high fat diet [528]; and BPA-induced insulin
esistance may  be additive with high fat diet [329]. Thus there are
merging data supporting a role for developmental exposures to
DCs in altering the set point of susceptibility for metabolic dis-
ases later in life. The second hit of high fat diet and lack of exercise
hen results in onset of the metabolic diseases.
Of course, throughout life there are likely to be multiple expo-
ures to MDCs that can also increase sensitivity to metabolic
isruption leading to weight gain, altered glucose tolerance and
ipid disorders. For example, young mice exposed to BPA for 30 days
howed signiﬁcantly increased body weight and fat mass on a chow
iet [330] but not on HFD (45%) which could be due to the over-
helming effect of the HFD. If true, then it would be difﬁcult to
ontrol or treat metabolic disorders with pharmaceuticals later in
ife, as they would need to be able to offset the increased sensitivityPlease cite this article in press as: J.J. Heindel, et al., Metabolism disru
http://dx.doi.org/10.1016/j.reprotox.2016.10.001
rogrammed during early development. Indeed, the current state
f science and medicine focuses on losing weight, and restoring
lucose homeostasis and liver lipids after they are disrupted; it is
lear that this approach is not working as the incidence of these PRESS
icology xxx (2016) xxx–xxx
diseases continues to increase. Furthermore, it is well documented
that while it is possible to lose weight and keep it off for an extended
time, the vast majority of people will gain the weight back, per-
haps indicating they are ﬁghting against a set point or sensitivity to
develop these metabolic problems that favors calorie storage over
the long term [434,435,620,621].
For this reason, a consequence of the MDC  hypothesis is that a
focus should be on prevention instead of intervention. If indeed a
set point for body weight, diabetes and/or METS is developed in
early life, then a better approach would be to focus on limiting fac-
tors that can alter programming during these sensitive times; for
example, addressing these metabolic epidemics will require reduc-
ing MDC  exposures and improving early-life nutrition. In this way,
the MDC  hypothesis offers the ability to actually prevent these dis-
eases, which is more cost effective and public health protective than
the current focus on interventions after the diseases are apparent.
Primary prevention measures must include up-to-date regulation
of chemicals: robust tools are needed in order to identify MDCs
among existing as well as new chemicals.
The MDC  hypothesis proposes both a mechanism for the
increased epidemic of obesity, diabetes and MetS and a solution.
If indeed these diseases are due in part to developmental expo-
sures to MDCs, as proposed, then for the ﬁrst time there is a path to
actually preventing them. The MDC  hypothesis changes the focus
from genetics to environmental exposures and from intervention
to prevention.
Peripheral signals reach the central nervous system through two
main routes:
Adiposity Signals (leptin, insulin and others) and hunger
(Ghrelin, Orexin A, and others) signals bypass the blood brain
barrier and target the hypothalamus (transparent blue circle), in
particular the arcuate nucleus (ARC).
b) Peripheral hunger and satiety signals that control meal process-
ing, gastrointestinal activity and changes in energy stores reach
the brainstem (nucleus of the solitary tract, NST) through vagal
and other sensory nerve ﬁbers.
NPY and MSH  neurons located within the ARC (stimulated or
inhibited by adiposity and hunger signals) project to other hypotha-
lamic nuclei (paraventricular nucleus, PVN, lateral hypothalamic
nucleus, LH, and others). In particular, within the PVN they control
CRH and TRH neurons, regulating (via the adenohypophysis) the
hypophysis-adrenal and hypophysis-thyroid axes.
From the hypothalamus, catabolic and anabolic pathways reach
the brainstem where their data are integrated with the peripheral
signals carried by the sensory system. There are also ascending pro-
jections from the NST that may reach the hypothalamus, through
the lemniscus visceralis, contributing to adaptative changes in food
intake and energy expenditure.
1. Mesenchymal stem cells commit to the adipogenic lineage and
become preadipocytes. Commitment to the adipocyte lineage
is mediated by transcription factors Zfp423, Zfp467, Schnurri2,
Tcf7l1 and the mTORC1 effector S6K1. 2. Adipocyte differenti-
ation is primarily controlled by PPAR and CCAAT-enchancer
binding proteins (C/EBP),  and  which establish a sustained
feedback loop. Numerous chemicals are capable of differenti-
ating pre-adipocytes into mature adipocytes. Adipocyte number
and size can be increased in vivo under hormonal control and canpting chemicals and metabolic disorders, Reprod Toxicol (2016),
also be inﬂuenced by chemical exposure. 3. Adipocyte hyperpla-
sia has been shown in rodents to be caused by perinatal exposure
to a variety of chemicals. 4. Adipocyte hypertrophy in rodents
due to permanent upregulation of genes involved in lipid uptake
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is also caused by exposure during perinatal life to a number of
chemicals.
Glucose enters pancreatic beta-cells through glucose trans-
orters (GLUT2 in mice and GLUT1 in humans) where it is
etabolized in mitochondria resulting in an increase in the
TP/ADP ratio; this results in closure of membrane ATP-sensitive
+ channels (KATP) that are responsible for the resting membrane
otential. KATP channel closure results in cellular depolarization
hat opens voltage-gated calcium channels, triggering Ca2+ signals
hat induce insulin granule exocytosis and a subsequent rise in cir-
ulating insulin levels. This secretory pathway is disrupted by EDCs
t different points: 1) Bisphenol-A, nonylphenol, octylphenol and
riphenyltin impair mitochondrial function. 2) Bisphenol-A blocks
ATP channels after binding ERbeta. 3) Calcium signaling is altered
y Bisphenol-A, Arsenic, PCBs and Triphenyltin. 4) disruption of
nsulin secretion has been described for Bisphenol-A, dioxins, PCBs,
DT, Arsenic, and Cadmium. Beta-cells have a low antioxidant
apacity and are very sensitive to oxidative stress mediated by
eactive oxygen and nitrogen species that impair their function by
ltering metabolism and/or KATP activity while inducing apoptosis.
ercury and Cadmium (5) are EDCs that produce oxidative stress
n beta-cells. 6) Insulin gene expression is regulated by BPA via
R,  while DEHP and Cadmium provoke cell death and decrease in
eta-cell mass.
Hepatic steatosis occurs due to a combination of increased fatty
cid (FA) synthesis or uptake and decrease FA oxidation or efﬂux.
A synthesis occurs as a consequence of liver X receptor (LXR)
arget gene activation which may  occur following receptor acti-
ation by myriad environmental chemicals or via nuclear receptor
ross talk. FA synthesis is upregulated by BPA, metals, PFCs, POPs,
nd tributyltin. BPA and POPs also upregulate scavenger receptors
e.g. CD36) to increase FA uptake into hepatocytes. Decreased FA
xidation is a consequence of mitochondrial dysfunction which
ay  be mediated by BPA, chlorinated solvents POPs and metals.
iver also mediates xenobiotic metabolism which may  increase
xidative stress. Endoplasmic reticulum (ER) stress is a conse-
uence of exposures to aldehydes and metals. ER stress, in turn,
mpacts FA metabolism. Steatohepatitis occurs due to increased
epatic inﬂammation and cytokines. Proinﬂammatory cytokines
re induced by many exposures including POPs, vinyl chloride,
OCs, and metals. More data are needed on the impact of MDCs
n FA efﬂux in hepatic steatosis.
unding
This review did not receive any speciﬁc grant from funding agen-
ies in the public, commercial or not-for-proﬁt sectors.
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